Data supplements: Meds Entry Watch, 10th Edition
Data supplement A: New International Medicines with sales 2021–2025
Data supplement A: New International Medicines with sales 2021–2025
| Approval cohort | Medicine (trade name, form, strength, volume) | ATC2 | Country of first sale or Approval body | Availability or First approval | First Sale in Canada | Percent of new medicine sales | no. OECD countries plus CAN US with sales | Treatment Cost | OECD Min | OECD max | Canadian price relative to midpoint of range | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medicine | ATC2 Class | Treatment Cost (CAD) | Annual/Course | ||||||||||
| 2021 | Abrocitinib (Cibinqo, abc film-ctd tabs, 200 mg, NA vol) | D5 Nonsteroidal products for inflammatory skin disorders | United Kingdom | 2021-10-01 | 2022-09-01 | 0.27% | 2.44% | 25 | 17,765 - 19,882 | Annual | $ 16 | $ 236 | Below |
| 2021 | Aducanumab (Aduhelm, fqc infus.via/bot., 100 mg/1 ml, 3 ml)B | N7 Other central nervous system drugs | United States | 2021-06-01 | – | 0.00% | 2.62% | 1 | 64.282 | Annual | $ 1,151 | $ 1,151 | NA |
| 2021 | Amivantamab (Rybrevant, fqc infus.via/bot., 50 mg/1 ml, 7 ml)B,C | L1 Antineoplastics | United States | 2021-06-01 | 2022-04-01 | 0.46% | 11.77% | 16 | 152.054 | Annual | $ 1,163 | $ 4,291 | Below |
| 2021 | Anifrolumab (Saphnelo, fqc infus.via/bot., 75 mg/1 ml, 2 ml)B | L4 Immunosuppressants | France | 2021-07-01 | 2022-03-01 | 0.64% | 3.24% | 20 | 21.934 | Annual | $ 698 | $ 6,673 | Below |
| 2021 | Asciminib (Scemblix, abc film-ctd tabs, 40 mg, NA vol)C,O | L1 Antineoplastics | United States | 2021-11-01 | 2022-09-01 | 1.04% | 11.77% | 25 | 62.092 | Annual | $ 63 | $ 456 | Below |
| 2021 | Atogepant (Qulipta, aaa tablets, 60 mg, NA vol) | N2 Analgesics | United States | 2021-10-01 | 2023-02-01 | 2.43% | 2.51% | 18 | 6.735 | Annual | $ 7 | $ 47 | Below |
| 2021 | Avacopan (Tavneos, aca capsules, 10 mg, NA vol)O | C6 Other cardiovascular products | United States | 2021-10-01 | 2022-11-01 | 0.57% | 0.71% | 17 | 75000 | Annual | $ 10 | $ 121 | Below |
| 2021 | Avalglucosidase alfa (Nexviazyme, fqd inf dry bottle, 100 mg, NA vol)B,O | A16 Other alimentary tract and metabolism products | United States | 2021-09-01 | 2022-02-01 | 0.60% | 0.90% | 15 | 534.563 | Annual | $ 1,041 | $ 2,291 | NEAR |
| 2021 | Belumosudil (Rezurock, aaa tablets, 200 mg, NA vol)O | L4 Immunosuppressants | United States | 2021-08-01 | 2023-03-01 | 0.61% | 3.24% | 5 | 496.525 | Annual | $ 216 | $ 216 | Above |
| 2021 | Belzutifan (Welireg, abc film-ctd tabs, 40 mg, NA vol)O | L1 Antineoplastics | United States | 2021-09-01 | 2022-08-01 | 0.63% | 11.77% | 5 | 17.920 | 28-day course | $ 206 | $ 425 | Below |
| 2021 | Bimekizumab (Bimzelx, fnh prefil autoinj, 160 mg/1 ml, 1 ml)B | L4 Immunosuppressants | Sweden | 2021-08-01 | 2022-03-01 | 1.80% | 3.24% | 25 | 30,631 / 22,921 | First / subsequent years | $ 336 | $ 9,713 | Below |
| 2021 | Casimersen (Amondys-45, fqc infus.via/bot., 50 mg/1 ml, 2 ml)O | M5 Other drugs for disorders of the musculo-skeletal system | United States | 2021-04-01 | – | 0.01% | 1.21% | 1 | 1,990,367 | Annual | $ 1,712 | $ 1,712 | NA |
| 2021 | Casirivimab (Ronapreve, fpa vial, 120 mg/1 ml+120 mg/1 ml, 2.5 ml)B | J6 Sera and gamma-globulin | United States | 2020-11-01 | – | 0.00% | 2.88% | 2 | – | – | $ 770 | $ 770 | NA |
| 2021 | Dasiglucagon (Zegalogue, fnh prefil autoinj, 1 mg/1 ml, 0.6 ml) | H4 Other hormones | United States | 2021-06-01 | – | 0.00% | 0.78% | 1 | 393 | Per utilization | $ 408 | $ 408 | NA |
| 2021 | Difelikefalin (Korsuva, fnc p-f syrng i.v., 35.7 y/1 ml, 0.7 ml) | D4 Anti-pruritics, including topical antihistamines, anaesthetics, etc | Netherlands | 2022-04-01 | 2023-02-01 | 0.07% | 0.07% | 14 | 4.212 | Annual | $ 26 | $ 26 | NA |
| 2021 | Dostarlimab (Jemperli, fqc infus.via/bot., 50 mg/1 ml, 10 ml)B,C | L1 Antineoplastics | France | 2020-11-01 | 2022-06-01 | 1.03% | 11.77% | 17 | 7,380 to 11,070 | 28-day course | $ 3,528 | $ 13,711 | Above |
| 2021 | Estetrol (Nextstellis, abc film-ctd tabs, 3 mg+15 mg, NA vol) | G3 Sex hormones and products with similar desired effects, systemic action only | Netherlands | 2021-05-01 | 2021-06-01 | 0.12% | 0.12% | 26 | 18 | 28-day course | $ 21 | $ 21 | Below |
| 2021 | Evinacumab (Evkeeza, fqc infus.via/bot., 150 mg/1 ml, 2.3 ml)B,O | C10 Lipid-regulating/anti-atheroma preparations | United States | 2021-05-01 | – | 0.06% | 0.06% | 8 | 4,823,753 | Annual | $ 1,846 | $ 16,570 | NA |
| 2021 | Finerenone (Kerendia, abc film-ctd tabs, 10 mg, NA vol) | C3 Diuretics | United States | 2021-07-01 | 2022-11-01 | 0.82% | 0.82% | 28 | 1.219 | Annual | $ 1 | $ 29 | Below |
| 2021 | Ibrexafungerp (Brexafemme, abc film-ctd tabs, 150 mg, NA vol) | G1 Gynaecological anti-infectives | United States | 2021-07-01 | – | 0.00% | 0.00% | 1 | 641 | Per treatment | $ 127 | $ 127 | NA |
| 2021 | Idecabtagene vicleucel (Abecma, fqe infusion bags, NA intstr, 50 ml)B,C,O | L1 Antineoplastics | France | 2021-05-01 | – | 0.31% | 11.77% | 4 | 545,000 | Treatment course | $ 402,285 | $ 402,285 | NA |
| 2021 | Infigratinib (Truseltiq, aca capsules, vari str, NA vol)C,O | L1 Antineoplastics | United States | 2021-07-01 | – | 0.00% | 11.77% | 0 | 15,713 | 28-day course | – | – | NA |
| 2021 | Lisocabtagene maraleucel (Breyanzi, fqc infus.via/bot., NA intstr, NA vol)B,C | L1 Antineoplastics | Japan | 2021-05-01 | – | 0.18% | 11.77% | 3 | 501,900 | One-time | $ 237,304 | $ 348,662 | NA |
| 2021 | Lonapegsomatropin (Skytrofa, grp u-d cartrg ret, 22 mg/1 ml, NA vol)B,O | H4 Other hormones | United States | 2021-11-01 | – | 0.47% | 0.78% | 2 | 38.894 | Annual | $ 2,457 | $ 2,457 | NA |
| 2021 | Loncastuximab tesirine (Zynlonta, fqd inf dry bottle, 10 mg, NA vol)B,C,O | L1 Antineoplastics | United States | 2021-05-01 | – | 0.08% | 11.77% | 7 | 23.752 | 28-day course | $ 6,266 | $ 32,642 | NA |
| 2021 | Maralixibat (Livmarli, dga oral liquid, 47.5 mg/5 ml, 30 ml)O | A5 Chologogues and hepatic protectors | Poland | 2023-01-01 | – | 0.09% | 0.51% | 10 | 259.734 | Annual | $ 5,748 | $ 11,666 | NA |
| 2021 | Maribavir (Livtencity, abc film-ctd tabs, 200 mg, NA vol) | J5 Antivirals for systemic use | United States | 2021-12-01 | 2023-01-01 | 0.23% | 4.91% | 20 | 58.128 | 7.5-week course | $ 0 | $ 337 | Above |
| 2021 | Melphalan flufenamide (Pepaxto, fqd inf dry bottle, 20 mg, NA vol)C,O | L1 Antineoplastics | United States | 2021-03-01 | – | 0.00% | 11.77% | 1 | 10.528 | 28-day course | $ 5,264 | $ 5,264 | NA |
| 2021 | Mobocertinib (Exkivity, aca capsules, 40 mg, NA vol)C,O | L1 Antineoplastics | United States | 2021-09-01 | – | 0.00% | 11.77% | 1 | 143.145 | Annual | $ 108 | $ 108 | NA |
| 2021 | Odevixibat (Bylvay, aca capsules, 1.2 mg, NA vol)O | A5 Chologogues and hepatic protectors | Sweden | 2021-07-01 | 2025-04-01 | 0.06% | 0.51% | 12 | 832.022 | Annual | $ 609 | $ 1,098 | NA |
| 2021 | Pegcetacoplan (Aspaveli, fqc infus.via/bot., 54 mg/1 ml, 20 ml)O | B6 All other haematological agents | United States | 2021-07-01 | – | 0.16% | 0.20% | 15 | 225.017 | Annual | $ 2,957 | $ 5,248 | NA |
| 2021 | Ponesimod (Ponvory, abc film-ctd tabs, 20 mg, NA vol) | N7 Other central nervous system drugs | United States | 2021-04-01 | – | 0.12% | 2.62% | 21 | 18.791 | Annual | $ 32 | $ 406 | NA |
| 2021 | Roxadustat (Evrenzo, abc film-ctd tabs, 50 mg, NA vol) | B3 Anti-anaemic preparations | Japan | 2019-11-01 | – | 0.05% | 0.30% | 20 | 8.182 | Annual | $ 4 | $ 24 | NA |
| 2021 | Samidorphan (Lybalvi, aaj layered tabs, 10 mg+10 mg, NA vol) | N5 Psycho-leptics | United States | 2021-10-01 | – | 0.37% | 0.51% | 1 | 22.364 | Annual | $ 71 | $ 71 | NA |
| 2021 | Serdexmethylphenidate (Azstarys, aca capsules, 7.8 mg+39.2 mg, NA vol) | N6 Psychoanaleptics excluding anti-obesity preparations | United States | 2021-07-01 | – | 0.37% | 0.46% | 1 | 6.122 | Annual | $ 19 | $ 19 | NA |
| 2021 | Somatrogon (Ngenla, frf p-f pens, 50 mg/1 ml, 1.2 ml)B,O | H4 Other hormones | Canada | 2022-02-01 | 2022-02-01 | 0.22% | 0.78% | 24 | 9.684 | Annual | $ 208 | $ 5,009 | Below |
| 2021 | Sotorasib (Lumakras, abc film-ctd tabs, 120 mg, NA vol)C,O | L1 Antineoplastics | United States | 2021-06-01 | 2021-10-01 | 0.36% | 11.77% | 24 | $ 11,024 | 28-day course | $ 23 | $ 106 | Below |
| 2021 | Tepotinib (Tepmetko, abc film-ctd tabs, 225 mg, NA vol)C,O | L1 Antineoplastics | Japan | 2020-06-01 | 2021-11-01 | 0.12% | 11.77% | 16 | $ 9,340 | Monthly course | $ 79 | $ 539 | Below |
| 2021 | Tezepelumab (Tezspire, fnh prefil autoinj, 110 mg/1 ml, 1.91 ml)B | R3 Anti-asthma and COPD products | United States | 2022-01-01 | 2022-10-01 | 2.00% | 2.07% | 23 | $ 25,200 | Annual | $ 846 | $ 5,562 | Below |
| 2021 | Tisotumab vedotin (Tivdak, fqd inf dry bottle, 40 mg, NA vol)B,C | L1 Antineoplastics | United States | 2022-03-01 | – | 0.00% | 11.77% | 1 | $ 273,159 | Annual | $ 8,497 | $ 8,497 | NA |
| 2021 | Tralokinumab (Adtralza, fne p-f syrng sc, 150 mg/1 ml, 1 ml)B | D5 Nonsteroidal products for inflammatory skin disorders | Sweden | 2021-06-01 | 2022-03-01 | 0.64% | 2.44% | 16 | $22,802 / $21,633 | First / subsequent years | $ 190 | $ 1,203 | Below |
| 2021 | Trilaciclib (Cosela, fqd inf dry bottle, 300 mg, NA vol)C | V3 All other therapeutic products | United States | 2021-03-01 | – | 0.08% | 0.15% | 1 | $ 3,611 | One-time | $ 1,993 | $ 1,993 | NA |
| 2021 | Vericiguat (Verquvo, abc film-ctd tabs, 2.5 mg, NA vol) | C6 Other cardiovascular products | United States | 2021-02-01 | 2023-09-01 | 0.13% | 0.71% | 25 | $ 1,763 | Annual | $ 1 | $ 29 | Below |
| 2021 | Viloxazine (Qelbree, bca retard caps, 200 mg, NA vol) | N7 Other central nervous system drugs | United States | 2021-05-01 | – | 0.48% | 2.62% | 1 | $2,496 to $9,986 | Annual | $ 16 | $ 16 | NA |
| 2021 | Voclosporin (Lupkynis, aca capsules, 7.9 mg, NA vol) | G4 Urologicals | United States | 2022-04-01 | – | 0.01% | 0.03% | 15 | $ 70,447 | Annual | $ 4 | $ 100 | NA |
| 2021 | Vosoritide (Voxzogo, fpb vial dry, 560 y, NA vol)O | M5 Other drugs for disorders of the musculo-skeletal system | France | 2021-07-01 | – | 0.37% | 1.21% | 12 | $ 168,478 | Annual | $ 685 | $ 1,162 | NA |
| 2022 | Adagrasib (Krazati, abc film-ctd tabs, 200 mg, NA vol)C,O | L1 Antineoplastics | United States | 2022-12-01 | – | 0.18% | 11.77% | 3 | $ 151,270 | Annual | $ 64 | $ 155 | NA |
| 2022 | Ciltacabtagene autoleucel (Carvykti, fqe infusion bags, NA intstr, NA vol)B,C,O | L1 Antineoplastics | Germany | 2023-02-01 | – | 0.18% | 11.77% | 1 | $ 632,455 | One-time | $ 425,106 | $ 425,106 | NA |
| 2022 | Daridorexant (Quviviq, abc film-ctd tabs, 50 mg, NA vol) | N5 Psycho-leptics | United States | 2022-04-01 | 2023-07-01 | 0.14% | 0.51% | 12 | $ 1,102 | Annual | $ 1 | $ 22 | Below |
| 2022 | Deucravacitinib (Sotyktu, abc film-ctd tabs, 6 mg, NA vol) | D5 Nonsteroidal products for inflammatory skin disorders | United States | 2022-09-01 | 2023-07-01 | 0.51% | 2.44% | 18 | $ 14,409 | Annual | $ 13 | $ 280 | Below |
| 2022 | Eflapegrastim (Rolvedon, gne p-f syr sc ret, 22 mg/1 ml, 0.6 ml)B | L3 Immunostimulating agents | Korea | 2022-10-01 | – | 0.11% | 0.12% | 1 | $ 5,209 | 21-day cycle | $ 4,003 | $ 4,003 | NA |
| 2022 | Eladocagene exuparvovec (Upstaza, fqc infus.via/bot., na intstr, 0.5 ml)B,O | N7 Other central nervous system drugs | Germany | 2022-08-01 | – | 0.01% | 2.62% | 1 | $ 4,720,827 | Single dose | $ 4,720,827 | $ 4,720,827 | NA |
| 2022 | Faricimab (Vabysmo, npa ophthal vials, 120 mg/1 ml, 0.24 ml)B | S1 Ophthalmologicals | United States | 2022-02-01 | 2022-07-01 | 5.31% | 6.71% | 27 | 8,100 / 4,050 | First / subsequent years | $ 608 | $ 1,330 | Above |
| 2022 | Futibatinib (Lytgobi, abc film-ctd tabs, 20 mg, NA vol)C,O | L1 Antineoplastics | United States | 2023-03-01 | – | 0.05% | 11.77% | 4 | $ 4,349 | 21-day cycle | $ 214 | $ 214 | NA |
| 2022 | Ganaxolone (Ztalmy, dgk suspension, 250 mg/5 ml, 110 ml)O | N3 Anti-epileptics | Poland | 2024-06-01 | – | 0.00% | 0.00% | 1 | $ 60,000 | Annual | $ 163 | $ 163 | NA |
| 2022 | Lenacapavir (Sunlenca, abc film-ctd tabs, 300 mg, NA vol) | J5 Antivirals for systemic use | Netherlands | 2022-08-01 | 2023-03-01 | 0.07% | 4.91% | 11 | $ 28,409 | Annual | $ 883 | $ 1,169 | Below |
| 2022 | Lutetium (177Lu) vipivotide tetraxetan (Pluvicto, fpc vial iv, NA intstr, 30 ml)C | V3 All other therapeutic products | Poland | 2023-07-01 | 2024-03-01 | 0.07% | 0.15% | 6 | $ 54,000 | 36-week course | – | – | NA |
| 2022 | Mavacamten (Camzyos, aca capsules, 5 mg, NA vol)O | C1 Cardiac therapy | United States | 2022-06-01 | 2023-08-01 | 0.67% | 0.67% | 17 | $ 22,484 | Annual | $ 54 | $ 348 | Below |
| 2022 | Mirvetuximab soravtansine (Elahere, fqc infus.via/bot., 5 mg/1 ml, 20 ml)B,C,O | L1 Antineoplastics | United States | 2023-03-01 | – | 0.26% | 11.77% | 2 | $ 37,448 | 21-day cycle | $ 4,475 | $ 7,882 | NA |
| 2022 | Mosunetuzumab (Lunsumio, fqc infus.via/bot., 1 mg/1 ml, 30 ml)B,C,O | L1 Antineoplastics | Sweden | 2022-06-01 | – | 0.06% | 11.77% | 12 | 9,726 to 19,451 | 21-day cycle | $ 8,770 | $ 23,101 | NA |
| 2022 | Nadofaragene firadenovec (Adstiladrin, mps top.instl.vial, NA intstr, 20 ml)B,C,O | L1 Antineoplastics | United States | 2023-09-01 | – | 0.10% | 11.77% | 1 | $ 345,136 | Annual | $ 21,571 | $ 21,571 | NA |
| 2022 | Nirmatrelvir (Paxlovid, abc film-ctd tabs, 150 mg+100 mg, NA vol) | J5 Antivirals for systemic use | United States | 2021-12-01 | 2022-01-01 | 4.60% | 4.91% | 29 | $ 10 | 5-day course | $ 23 | $ 77 | Above |
| 2022 | Nirsevimab (Beyfortus, fnd pre-fill i.m, 100 mg/1 ml, 1 ml)B | J6 Sera and gamma-globulin | Spain | 2023-09-01 | – | 2.88% | 2.88% | 10 | $ 4,437 | One-time | $ 321 | $ 6,588 | NA |
| 2022 | Olipudase alfa (Xenpozyme, fqd inf dry bottle, 20 mg, NA vol)B,O | A16 Other alimentary tract and metabolism products | Portugal | 2022-05-01 | – | 0.22% | 0.90% | 12 | $ 1,297,808 | Annual (maintenance phase) | $ 0 | $ 9,329 | NA |
| 2022 | Olutasidenib (Rezlidhia, aca capsules, 150 mg, NA vol)C,O | L1 Antineoplastics | United States | 2022-12-01 | – | 0.02% | 11.77% | 1 | $ 459,858 | Annual | $ 678 | $ 678 | NA |
| 2022 | Omidenepag (Eybelis, ngb drops eye, 20 y/1 ml, 2.5 ml) | S1 Ophthalmologicals | Japan | 2018-11-01 | – | 0.04% | 6.71% | 2 | $ 2 | Annual | $ 0 | $ 0 | NA |
| 2022 | Oteseconazole (Vivjoa, aca capsules, 150 mg, NA vol) | G1 Gynaecological anti-infectives | United States | 2022-08-01 | – | 0.00% | 0.00% | 1 | $ 3,735 | 12-week course | $ 221 | $ 221 | NA |
| 2022 | Pacritinib (Vonjo, aca capsules, 100 mg, NA vol)O | L1 Antineoplastics | United States | 2022-03-01 | – | 0.06% | 11.77% | 1 | $ 403,372 | Annual | $ 254 | $ 254 | NA |
| 2022 | Palovarotene (Sohonos, aca capsules, 5 mg, NA vol)O | M5 Other drugs for disorders of the musculo-skeletal system | United States | 2023-11-01 | – | 0.02% | 1.21% | 1 | $ 1,022,894 | Annual | $ 2,095 | $ 2,095 | NA |
| 2022 | Relatlimab (Opdualag, fqc infus.via/bot., 12 mg/1 ml+4 mg/1 ml, 20 ml)B,C,O | L1 Antineoplastics | United States | 2022-03-01 | 2024-02-01 | 1.16% | 11.77% | 11 | $ 446,383 | Annual | $ 8,278 | $ 18,195 | Below |
| 2022 | Spesolimab (Spevigo, fqc infus.via/bot., 60 mg/1 ml, 7.5 ml)B,O | D5 Nonsteroidal products for inflammatory skin disorders | United States | 2022-09-01 | 2023-05-01 | 0.06% | 2.44% | 9 | $ 21,771 | One-time | $ 11,751 | $ 36,800 | Below |
| 2022 | Sutimlimab (Enjaymo, fpc vial iv, 50 mg/1 ml, 22 ml)B,O | B3 Anti-anaemic preparations | United States | 2022-02-01 | – | 0.13% | 0.30% | 5 | $ 417,635 | Annual | $ 2,414 | $ 2,414 | NA |
| 2022 | Tabelecleucel (Ebvallo, fqc infus.via/bot., NA intstr, 1 ml)C,O | L1 Antineoplastics | Germany | 2023-05-01 | – | 0.00% | 11.77% | 1 | $ 413,500 | 35-day course | $ 82,700 | $ 82,700 | NA |
| 2022 | Tapinarof (Vtama, mta cream, 1%, 60 g) | D5 Nonsteroidal products for inflammatory skin disorders | United States | 2022-05-01 | – | 0.32% | 2.44% | 2 | $ 172 | Annual | $ 30 | $ 30 | NA |
| 2022 | Tebentafusp (Kimmtrak, fqc infus.via/bot., 200 y/1 ml, 0.5 ml)B,C,O | L1 Antineoplastics | United States | 2022-02-01 | 2023-12-01 | 0.66% | 11.77% | 16 | $ 74,260 | 28-day cycle | $ 4,188 | $ 27,673 | NEAR |
| 2022 | Teclistamab (Tecvayli, fpe vial sc, 90 mg/1 ml, 1.7 ml)B,C,O | L1 Antineoplastics | Poland | 2022-09-01 | 2025-05-01 | 0.65% | 11.77% | 17 | $ 404,057 | Annual | $ 0 | $ 11,587 | NA |
| 2022 | Teplizumab (Tzield, fqc infus.via/bot., 1 mg/1 ml, 2 ml)B | A10 Drugs used in diabetes | United States | 2022-12-01 | – | 0.06% | 46.98% | 1 | $ 109,395 | 14-day treatment | $ 20,907 | $ 20,907 | NA |
| 2022 | Terlipressin (Terlivaz, fpb vial dry, 850 y, NA vol) | H4 Other hormones | Germany | 1978-01-01 | – | 0.04% | 0.78% | 21 | $ 63,900 | 14-day treatment | $ 1,245 | $ 1,245 | NA |
| 2022 | Tirzepatide (Mounjaro, fpe vial sc, 10 mg/1 ml, 0.5 ml) | A10 Drugs used in diabetes | Poland | 2022-06-01 | 2023-10-01 | 46.91% | 46.98% | 22 | $ 4,107 | Annual | $ 51 | $ 123 | Below |
| 2022 | Tixagevimab (Evusheld, fpd vial im, 150 mg/1 ml+150 mg/1 ml, 1.5 ml)B | J6 Sera and gamma-globulin | France | 2021-12-01 | 2022-05-01 | 0.00% | 2.88% | 3 | $ 11,667 | Annual | $ 1,599 | $ 1,599 | NA |
| 2022 | Tremelimumab (Imjudo, fqc infus.via/bot., 20 mg/1 ml, 15 ml)B,C,O | L1 Antineoplastics | United States | 2022-11-01 | 2023-10-01 | 0.36% | 11.77% | 15 | $ 34,117 | One-time | $ 16,793 | $ 48,011 | NEAR |
| 2022 | Ublituximab (Briumvi, fqc infus.via/bot., 25 mg/1 ml, 6 ml)B,O | N7 Other central nervous system drugs | United States | 2023-01-01 | – | 0.06% | 2.62% | 5 | $ 86,321 | Annual | $ 3,807 | $ 13,207 | NA |
| 2022 | Ursodoxicoltaurine (Tudcabil, aca capsules, 250 mg, NA vol)B | A5 Chologogues and hepatic protectors | Italy | 1992-01-01 | 2023-03-01 | 0.00% | 0.51% | 1 | $ 168,052 | Annual | $ 0 | $ 0 | NA |
| 2022 | Vaccine, dengue fever (Qdenga, fpb vial dry, NA intstr, NA vol)B | J7 Vaccines | Mexico | 2022-12-01 | – | 0.02% | 2.94% | 16 | $ 114 | One-time | $ 108 | $ 168 | NA |
| 2022 | Valoctocogene roxaparvovec (Roctavian, fqc infus.via/bot., NA intstr, 8 ml)B,O | B2 Blood coagulation system, other products | Italy | 2024-03-01 | – | 0.07% | 1.10% | 2 | $ 2,127,372 | Single dose | $ 81,822 | $ 81,822 | NA |
| 2022 | Vonoprazan (Takecab, abc film-ctd tabs, 10 mg, NA vol) | A2 Antacids, antiflatulents and anti-ulcerants | Japan | 2015-02-01 | – | 1.01% | 1.01% | 2 | $ 213 | 8-month treatment | $ 1 | $ 1 | NA |
| 2022 | Vutrisiran (Amvuttra, fne p-f syrng sc, 50 mg/1 ml, 0.5 ml)O | N7 Other central nervous system drugs | United States | 2022-07-01 | – | 1.26% | 2.62% | 11 | $ 546,045 | Annual | $ 97,202 | $ 151,814 | NA |
| 2023 | Apadamtase alfa (Adzynma, fqd inf dry bottle, 1.5 k, NA vol)B,O | B1 Antithrombotic agents | United States | 2023-12-01 | – | 0.06% | 0.06% | 5 | $ 111,948 | Annual | $ 6,820 | $ 8,810 | NA |
| 2023 | Avacincaptad pegol (Izervay, npa ophthal vials, 20 mg/1 ml, 0.1 ml) | S1 Ophthalmologicals | United States | 2023-09-01 | – | 0.45% | 6.71% | 1 | $ 3,650 | Annual | $ 2,829 | $ 2,829 | NA |
| 2023 | Beremagene geperpavec (Vyjuvek, mva gel/sol top., NA intstr, 1.5 ml)B,O | D3 Wound healing agents | United States | 2023-12-01 | – | 0.00% | 0.00% | 0 | $ 577,480 | Annual | – | – | NA |
| 2023 | Bexagliflozin (Brenzavvy, abc film-ctd tabs, 20 mg, NA vol) | A10 Drugs used in diabetes | United States | 2023-12-01 | – | 0.00% | 46.98% | 1 | $ 730 | Annual | $ 2 | $ 2 | NA |
| 2023 | Capivasertib (Truqap, abc film-ctd tabs, 200 mg, NA vol)C | L1 Antineoplastics | United States | 2023-12-01 | 2024-04-01 | 0.65% | 11.77% | 10 | $ 9,446 | 28-day cycle | $ 82 | $ 453 | Below |
| 2023 | Cipaglucosidase alfa (Pombiliti, fqd inf dry bottle, 105 mg, NA vol)B,O | A16 Other alimentary tract and metabolism products | Portugal | 2023-03-01 | – | 0.04% | 0.90% | 4 | $ 646,586 | Annual | $ 1,456 | $ 2,201 | NA |
| 2023 | Concizumab (Alhemo, frf p-f pens, 100 mg/1 ml, NA vol)B,O | B2 Blood coagulation system, other products | France | 2023-11-01 | – | 0.01% | 1.10% | 1 | $ 652,036 | Annual | $ 13,760 | $ 13,760 | NA |
| 2023 | Daprodustat (Duvroq, abc film-ctd tabs, 4 mg, NA vol) | B3 Anti-anaemic preparations | Japan | 2020-08-01 | – | 0.10% | 0.30% | 2 | $ 4,815 | Annual | $ 2 | $ 2 | NA |
| 2023 | Delandistrogene moxeparvovec (Elevidys, fqc infus.via/bot., NA intstr, NA vol)B,O | M5 Other drugs for disorders of the musculo-skeletal system | United States | 2023-09-01 | – | 0.48% | 1.21% | 1 | $ 81,067 | Single dose | $ 81,067 | $ 81,067 | NA |
| 2023 | Efanesoctocog alfa (Altuviiio, fqd inf dry bottle, 4 k, NA vol)B,O | B2 Blood coagulation system, other products | United States | 2023-04-01 | – | 1.02% | 1.10% | 6 | $ 279,875 | Annual | $ 5,762 | $ 21,504 | NA |
| 2023 | Efbemalenograstim alfa (Ryzneuta, fne p-f syrng sc ret, 20 mg/1 ml, 1 ml)B,C | L3 Immunostimulating agents | Germany | 2024-08-01 | – | 0.00% | 0.12% | 1 | $ 22,000 | Annual | $ 1,267 | $ 1,267 | NA |
| 2023 | Elranatamab (Elrexfio, fpe vial sc, 40 mg/1 ml, 1.9 ml)B,C,O | L1 Antineoplastics | Slovenia | 2023-09-01 | 2024-03-01 | 0.31% | 11.77% | 14 | $ 28,000 | 21-day cycle | $ 7,223 | $ 16,157 | Below |
| 2023 | Epcoritamab (Epkinly, fpe vial sc, 60 mg/1 ml, 0.8 ml)B,C,O | L1 Antineoplastics | Sweden | 2023-09-01 | 2023-12-01 | 0.26% | 11.77% | 12 | $ 14,320 | 28-day cycle | $ 11,596 | $ 21,538 | NA |
| 2023 | Eplontersen (Wainua, fnh prefil autoinj, 56.3 mg/1 ml, 0.8 ml)O | N7 Other central nervous system drugs | United States | 2024-01-01 | 2024-10-01 | 0.16% | 2.62% | 2 | $ 570,120 | Annual | $ 50,039 | $ 50,039 | Below |
| 2023 | Etrasimod (Velsipity, abc film-ctd tabs, 2 mg, NA vol) | A7 Antidiarrhoeals, oral electrolyte replacers and intestinal anti-inflammatories | United States | 2023-12-01 | 2024-04-01 | 0.03% | 0.29% | 12 | $ 15,742 | Annual | $ 32 | $ 256 | Below |
| 2023 | Fecal microbiota spores, live (Vowst, aca capsules, NA intstr, NA vol)B,O | A7 Antidiarrhoeals, oral electrolyte replacers and intestinal anti-inflammatories | United States | 2023-06-01 | – | 0.01% | 0.29% | 1 | $ 23,547 | 3-day treatment | $ 1,903 | $ 1,903 | NA |
| 2023 | Fezolinetant (Veozah, abc film-ctd tabs, 45 mg, NA vol) | G2 Other gynaecologicals | United States | 2023-05-01 | 2025-03-01 | 0.44% | 0.44% | 14 | $ 8,695 | Annual | $ 2 | $ 24 | NA |
| 2023 | Fruquintinib (Fruzaqla, aca capsules, 5 mg, NA vol)C | L1 Antineoplastics | United States | 2023-11-01 | 2025-04-01 | 0.37% | 11.77% | 10 | $ 424,229 | Annual | $ 173 | $ 1,508 | NA |
| 2023 | Gefapixant (Lyfnua, abc film-ctd tabs, 45 mg, NA vol) | R5 Cough and cold preparations | Japan | 2022-04-01 | – | 0.01% | 0.01% | 11 | $ 1,014 | Annual | $ 1 | $ 3 | NA |
| 2023 | Glofitamab (Columvi, fqc infus.via/bot., 1 mg/1 ml, 10 ml)B,C,O | L1 Antineoplastics | Portugal | 2023-06-01 | 2023-08-01 | 0.18% | 11.77% | 15 | $ 12,480 | 21-day cycle | $ 4,311 | $ 13,300 | Below |
| 2023 | Iptacopan (Fabhalta, aca capsules, 200 mg, NA vol)O | L4 Immunosuppressants | United States | 2023-12-01 | – | 0.19% | 3.24% | 7 | $ 489,830 | Annual | $ 0 | $ 1,031 | NA |
| 2023 | Lebrikizumab (Ebglyss, fnh prefil autoinj, 125 mg/1 ml, 2 ml)B | D5 Nonsteroidal products for inflammatory skin disorders | Netherlands | 2023-11-01 | 2024-09-01 | 0.19% | 2.44% | 11 | $ 24,397 | Annual | $ 1,404 | $ 1,807 | Above |
| 2023 | Lecanemab (Leqembi, fqc infus.via/bot., 100 mg/1 ml, 2 ml)B | N7 Other central nervous system drugs | United States | 2023-01-01 | – | 0.31% | 2.62% | 2 | $ 32,327 | Annual | $ 318 | $ 333 | NA |
| 2023 | Lotilaner (Xdemvy, ngb drops eye, 0.25%, 10 ml) | S1 Ophthalmologicals | United States | 2023-09-01 | – | 0.20% | 6.71% | 1 | $ 12 | 6-week treatment | $ 13 | $ 13 | NA |
| 2023 | Mirikizumab (Omvoh, fnh prefil autoinj, 100 mg/1 ml, 1 ml)B,O | A7 Antidiarrhoeals, oral electrolyte replacers and intestinal anti-inflammatories | Sweden | 2023-05-01 | 2023-10-01 | 0.25% | 0.29% | 16 | $ 30,977 | Annual | $ 339 | $ 6,550 | Below |
| 2023 | Momelotinib (Ojjaara, abc film-ctd tabs, 200 mg, NA vol)C,O | L1 Antineoplastics | France | 2023-04-01 | 2025-01-01 | 0.46% | 11.77% | 8 | $ 401,628 | Annual | $ 225 | $ 1,144 | NA |
| 2023 | Motixafortide (Aphexda, fpb vial dry, 62 mg, NA vol)C,O | L3 Immunostimulating agents | United States | 2023-11-01 | – | 0.01% | 0.12% | 1 | $ 11,535 | One time | $ 7,113 | $ 7,113 | NA |
| 2023 | Nedosiran (Rivfloza, fne p-f syrng sc, 160 mg/1 ml, 1 ml)O | G4 Urologicals | United States | 2024-04-01 | – | 0.00% | 0.03% | 1 | $ 926,064 | Annual | $ 77,172 | $ 77,172 | NA |
| 2023 | Nirogacestat (Ogsiveo, abc film-ctd tabs, 50 mg, NA vol)C | L1 Antineoplastics | United States | 2023-12-01 | – | 0.00% | 11.77% | 2 | $ 425,446 | Annual | $ 189 | $ 325 | NA |
| 2023 | Omaveloxolone (Skyclarys, aca capsules, 50 mg, NA vol)O | N7 Other central nervous system drugs | France | 2024-01-01 | – | 0.15% | 2.62% | 6 | $ 425,955 | Annual | $ 383 | $ 452 | NA |
| 2023 | Palopegteriparatide (Yorvipath, grf p-f pens ret, 300 y/1 ml, 0.98 ml)O | H4 Other hormones | Austria | 2024-01-01 | – | 0.04% | 0.78% | 2 | $ 2,401,700 | Annual | $ 6,526 | $ 6,635 | NA |
| 2023 | Pegunigalsidase alfa (Elfabrio, fqc infus.via/bot., 2 mg/1 ml, 10 ml)B | A16 Other alimentary tract and metabolism products | Norway | 2023-07-01 | – | 0.04% | 0.90% | 10 | $ 421,382 | Annual | $ 2,131 | $ 5,310 | NA |
| 2023 | Pegzilarginase (Loargys, gpa vial ret, 5 mg/1 ml, 0.4 ml)B,O | A16 Other alimentary tract and metabolism products | Germany | 2024-01-01 | – | 0.01% | 0.90% | 4 | $ 2,958,325 | Annual | $ 7,355 | $ 8,515 | NA |
| 2023 | Perfluorohexyloctane (Miebo, ngb drops eye, 100%, 3 ml) | S1 Ophthalmologicals | United States | 2023-09-01 | – | 0.70% | 6.71% | 1 | NA (drops) | NA (drops) | $ 17 | $ 17 | NA |
| 2023 | Pirtobrutinib (Jaypirca, abc film-ctd tabs, 100 mg, NA vol)C,O | L1 Antineoplastics | United States | 2023-02-01 | – | 0.39% | 11.77% | 15 | $ 319,679 | Annual | $ 0 | $ 460 | NA |
| 2023 | Quizartinib (Vanflyta, abc film-ctd tabs, 17.7 mg, NA vol)C,O | L1 Antineoplastics | Japan | 2019-10-01 | – | 0.05% | 11.77% | 5 | $ 107,072 | Annual | $ 146 | $ 700 | NA |
| 2023 | Repotrectinib (Augtyro, aca capsules, 40 mg, NA vol)C,O | L1 Antineoplastics | United States | 2023-12-01 | – | 0.05% | 11.77% | 2 | $ 468,941 | Annual | $ 25 | $ 163 | NA |
| 2023 | Retifanlimab (Zynyz, fqc infus.via/bot., 25 mg/1 ml, 20 ml)B,C,O | L1 Antineoplastics | United States | 2023-04-01 | – | 0.00% | 11.77% | 1 | $ 235,963 | Annual | $ 17,706 | $ 17,706 | NA |
| 2023 | Rezafungin (Rezzayo, fqd inf dry bottle, 200 mg, NA vol)O | J2 Systemic agents for fungal infections | United States | 2023-08-01 | – | 0.01% | 0.01% | 4 | $ 15,466 | 5-week treatment | $ 2,612 | $ 3,533 | NA |
| 2023 | Ritlecitinib (Litfulo, aca capsules, 50 mg, NA vol) | D5 Nonsteroidal products for inflammatory skin disorders | Portugal | 2023-07-01 | 2024-02-01 | 0.21% | 2.44% | 16 | $ 15,339 | Annual | $ 1 | $ 179 | Below |
| 2023 | Rozanolixizumab (Rystiggo, fqc infus.via/bot., 140 mg/1 ml, 2 ml)B,O | M5 Other drugs for disorders of the musculo-skeletal system | United States | 2023-07-01 | – | 0.25% | 1.21% | 4 | $ 388,082 | Annual | $ 8,192 | $ 14,039 | NA |
| 2023 | Sparsentan (Filspari, abc film-ctd tabs, 400 mg, NA vol)O | G4 Urologicals | United States | 2023-03-01 | – | 0.01% | 0.03% | 3 | $ 141,989 | Annual | $ 197 | $ 198 | NA |
| 2023 | Talquetamab (Talvey, fpe vial sc, 40 mg/1 ml, 1 ml)B,C,O | L1 Antineoplastics | Portugal | 2023-08-01 | – | 0.36% | 11.77% | 13 | $ 41,629 | 21-day course | $ 6,549 | $ 12,525 | NA |
| 2023 | Tislelizumab (Bai Ze An, fqc infus.via/bot., 10 mg/1 ml, 10 ml)B,C,O | L1 Antineoplastics | Norway | 2024-07-01 | – | 0.00% | 11.77% | 5 | $ 94,528 | Annual | $ 2,715 | $ 7,362 | NA |
| 2023 | Tofersen (Qalsody, fpy vial other, 6.67 mg/1 ml, 15 ml)O | N7 Other central nervous system drugs | France | 2022-12-01 | – | 0.03% | 2.62% | 4 | $ 465,794 | Annual | $ 29,993 | $ 35,138 | NA |
| 2023 | Toripalimab (Loqtorzi, fqc infus.via/bot., 40 mg/1 ml, 6 ml)B,C,O | L1 Antineoplastics | United States | 2023-12-01 | – | 0.03% | 11.77% | 1 | $ 190,476 | Annual | $ 10,989 | $ 10,989 | NA |
| 2023 | Vaccine, respiratory syncytial virus (Abrysvo, fpb vial dry, 60 y, NA vol)B | J7 Vaccines | Netherlands | 2023-06-01 | 2023-09-01 | 2.43% | 2.94% | 26 | $ 225 | One-time | – | – | NA |
| 2023 | Vadadustat (Vafseo, abc film-ctd tabs, 300 mg, NA vol) | B3 Anti-anaemic preparations | Japan | 2020-08-01 | – | 0.02% | 0.30% | 4 | $ 935 | Annual | $ 2 | $ 59 | NA |
| 2023 | Vamorolone (Agamree, dgk suspension, 200 mg/5 ml, 100 ml)O | M5 Other drugs for disorders of the musculo-skeletal system | Germany | 2024-01-01 | – | 0.03% | 1.21% | 2 | $ 8,979 | Annual | $ 410 | $ 410 | NA |
| 2023 | Zavegepant (Zavzpret, ign n sys u-d liq, 10 mg/dose, NA vol) | N2 Analgesics | United States | 2023-06-01 | – | 0.09% | 2.51% | 1 | $ 20,085 | 14-day treatment | $ 240 | $ 240 | NA |
| 2023 | Zilucoplan (Zilbrysq, fne p-f syrng sc, 40 mg/1 ml, 0.81 ml)O | M5 Other drugs for disorders of the musculo-skeletal system | Germany | 2024-03-01 | – | 0.05% | 1.21% | 3 | $ 423,035 | Annual | $ 1,127 | $ 1,190 | NA |
| 2023 | Zuranolone (Zurzuvae, aca capsules, 25 mg, NA vol) | N6 Psychoanaleptics excluding anti-obesity preparations | United States | 2023-12-01 | – | 0.10% | 0.46% | 1 | $ 20,000 | 14-day treatment | $ 738 | $ 738 | NA |
| 2024 | Acoramidis (Attruby, abc film-ctd tabs, 356 mg, NA vol)O | C1 Cardiac therapy | United States | 2024-12-01 | – | 0.00% | 0.67% | 1 | $ 323,762 | Annual | $ 222 | $ 222 | NA |
| 2024 | Aprocitentan (Tryvio, abc film-ctd tabs, 12.5 mg, NA vol) | C2 Antihypertensives | United States | 2024-10-01 | – | 0.00% | 0.00% | 1 | $ 11,549 | Annual | $ 32 | $ 32 | NA |
| 2024 | Crovalimab (Piasky, fpa vial, 170 mg/1 ml, 2 ml)B,O | B6 All other haematological agents | Japan | 2024-05-01 | – | 0.04% | 0.20% | 2 | $ 424,060 | Annual | $ 14,378 | $ 18,215 | NA |
| 2024 | Danicopan (Voydeya, abc film-ctd tabs, na intstr, NA vol)O | B6 All other haematological agents | Germany | 2024-06-01 | – | 0.00% | 0.20% | 1 | $ 85,282 | Annual | $ 56 | $ 56 | NA |
| 2024 | Delgocitinib (Corectim, msa ointment, 0.5%, 5 g) | D5 Nonsteroidal products for inflammatory skin disorders | Japan | 2020-06-01 | – | 0.08% | 2.44% | 2 | $637 to $5,096 | Annual | $ 1 | $ 1 | NA |
| 2024 | Donanemab (Kisunla, fqc infus.via/bot., 17.5 mg/1 ml, 20 ml)B | N7 Other central nervous system drugs | United States | 2024-07-01 | – | 0.03% | 2.62% | 2 | $ 47,981 | Annual | $ 923 | $ 923 | NA |
| 2024 | Elafibranor (Iqirvo, abc film-ctd tabs, 80 mg, NA vol)O | A5 Chologogues and hepatic protectors | United States | 2024-06-01 | 2025-05-01 | 0.06% | 0.51% | 4 | $ 19,055 | 3-month cycle | $ 151 | $ 471 | NA |
| 2024 | Ensifentrine (Ohtuvayre, rgn lung u-d liq, 3 mg/dose, 2.5 ml) | R3 Anti-asthma and COPD products | United States | 2024-07-01 | – | 0.08% | 2.07% | 1 | $ 43,954 | Annual | $ 60 | $ 60 | NA |
| 2024 | Imetelstat (Rytelo, fqd inf dry bottle, 188 mg, NA vol)B,C | L1 Antineoplastics | United States | 2024-06-01 | – | 0.18% | 11.77% | 1 | $ 37,492 | 28-day course | $ 12,497 | $ 12,497 | NA |
| 2024 | Inavolisib (Itovebi, abc film-ctd tabs, 9 mg, NA vol)C | L1 Antineoplastics | United States | 2024-11-01 | – | 0.01% | 11.77% | 1 | $ 16,732 | 28-day course | $ 1,067 | $ 1,067 | NA |
| 2024 | Insulin icodec (Awiqli, grf p-f pens ret, 700 iu/1 ml, 3 ml)B | A10 Drugs used in diabetes | Canada | 2024-06-01 | 2024-06-01 | 0.01% | 46.98% | 2 | <$10k | Annual | $ 147 | $ 147 | Above |
| 2024 | Iomeprol (Iomeron, fpa vial, 350 mg/1 ml, 500 ml) | T1 Diagnostic imaging | Japan | 1994-05-01 | – | 0.38% | 0.38% | 18 | $ 191 | Single dose | $ 0 | $ 317 | NA |
| 2024 | Lazertinib (Lazcluze, abc film-ctd tabs, 240 mg, NA vol)C | L1 Antineoplastics | Korea | 2024-09-01 | 2025-04-01 | 0.11% | 11.77% | 2 | $ 12,135 | 28-day course | $ 779 | $ 779 | NA |
| 2024 | Marstacimab (Hympavzi, fnh prefil autoinj, 150 mg/1 ml, 1 ml)B,O | B2 Blood coagulation system, other products | United States | 2024-12-01 | – | 0.00% | 1.10% | 1 | $ 1,041,679 | Annual | $ 20,032 | $ 20,032 | NA |
| 2024 | Nemolizumab (Nemluvio, fnh prefil autoinj, na intstr, NA vol)B | D5 Nonsteroidal products for inflammatory skin disorders | Japan | 2022-08-01 | – | 0.15% | 2.44% | 2 | $ 74,301 | Annual | $ 5,715 | $ 5,715 | NA |
| 2024 | Nogapendekin alfa inbakicept (Anktiva, mpa top/ext. vials, 1 mg/1 ml, 0.4 ml)C | L1 Antineoplastics | United States | 2024-06-01 | – | 0.04% | 11.77% | 1 | $ 88,729 | Annual | $ 44,365 | $ 44,365 | NA |
| 2024 | Resmetirom (Rezdiffra, abc film-ctd tabs, 80 mg, NA vol) | A5 Chologogues and hepatic protectors | United States | 2024-04-01 | – | 0.17% | 0.51% | 1 | $ 54,020 | Annual | $ 148 | $ 148 | NA |
| 2024 | Revumenib (Revuforj, abc film-ctd tabs, 110 mg, NA vol)C,O | L1 Antineoplastics | United States | 2024-12-01 | – | 0.00% | 11.77% | 1 | $ 1,278,766 | Annual | $ 876 | $ 876 | NA |
| 2024 | Seladelpar (Livdelzi, aca capsules, 10 mg, NA vol)O | A5 Chologogues and hepatic protectors | United States | 2024-08-01 | – | 0.13% | 0.51% | 1 | $ 208,427 | Annual | $ 571 | $ 571 | NA |
| 2024 | Sofpironium (Ecclock, mva gel/sol top., 5%, 40 g) | D2 Emollients, protectives | Japan | 2020-11-01 | – | 0.01% | 0.01% | 1 | NA (cream) | NA (cream) | $ 2 | $ 2 | NA |
| 2024 | Sotatercept (Winrevair, fpb vial dry, 45 mg, NA vol)B,O | C6 Other cardiovascular products | United States | 2024-06-01 | 2025-02-01 | 0.02% | 0.71% | 5 | $ 186,523 | Annual | $ 9,456 | $ 18,458 | NA |
| 2024 | Tarlatamab (Imdelltra, fqd inf dry bottle, 10 mg, NA vol)B,C,O | L1 Antineoplastics | United States | 2024-05-01 | 2024-11-01 | 0.29% | 11.77% | 1 | $ 27,740 | 28-day course | $ 18,597 | $ 18,597 | NA |
| 2024 | Vorasidenib (Voranigo, abc film-ctd tabs, 40 mg, NA vol)C,O | L1 Antineoplastics | Portugal | 2024-08-01 | 2025-03-01 | 0.01% | 11.77% | 2 | $ 597,152 | Annual | $ 466 | $ 1,636 | NA |
| 2024 | Zolbetuximab (Vyloy, fqd inf dry bottle, 100 mg, NA vol)B,C,O | L1 Antineoplastics | Japan | 2024-06-01 | 2025-04-01 | 0.07% | 11.77% | 5 | $ 131,542 | 28-day course | $ 396 | $ 2,064 | NA |
| 2025 | Aceclidine (Vizz) | – | FDA | 2025-07-31 | 2025-07-31 | ||||||||
| 2025 | Acoltremon (Tryptyr) | – | FDA | 2025-05-28 | 2025-05-28 | ||||||||
| 2025 | Aficamten (Myqorzo)O | – | FDA | 2025-12-19 | 2025-12-19 | ||||||||
| 2025 | Allogeneic umbilical cord-derived cd34- cells)B,C,O | – | EMA | 2025-08-25 | 2025-08-25 | ||||||||
| 2025 | Atrasentan (Vanrafia) | – | FDA | 2025-04-02 | 2025-04-02 | ||||||||
| 2025 | Avutometinib and defactinib (Avmapki fakzynja co-pack)C,O | – | FDA | 2025-05-08 | 2025-05-08 | ||||||||
| 2025 | Belantamab mafodotin (Blenrep)B,C,O | – | HC | 2025-07-18 | 2025-10-23 | 2025-07-23 | 2025-07-18 | ||||||
| 2025 | Beremagene geperpavec (Vyjuvek)B,O | – | EMA | 2025-04-23 | 2025-09-12 | 2025-04-23 | |||||||
| 2025 | Brensocatib (Brinsupri) | – | FDA | 2025-08-12 | 2025-08-12 | 2025-11-18 | |||||||
| 2025 | Chikungunya virus (Chikv) virus-like particle (Vlp) (Vimkunya)B | – | FDA | 2025-02-14 | 2025-02-14 | 2025-02-28 | |||||||
| 2025 | Clesrovimab (Enflonsia)B | – | FDA | 2025-06-09 | 2025-06-09 | ||||||||
| 2025 | Datopotamab deruxtecan (Datroway)B,C | – | FDA | 2025-01-17 | 2025-01-17 | 2025-04-04 | |||||||
| 2025 | Delgocitinib (Anzupgo) | – | FDA | 2025-07-23 | 2025-07-23 | 2025-09-19 | 2025-08-25 | ||||||
| 2025 | Depemokimab (Exdensur)B | – | FDA | 2025-12-16 | 2025-12-16 | ||||||||
| 2025 | Donidalorsen (Dawnzera)O | – | FDA | 2025-08-21 | 2025-08-21 | ||||||||
| 2025 | Dordaviprone (Modeyso)C,O | – | FDA | 2025-08-06 | 2025-08-06 | ||||||||
| 2025 | Doxecitine and doxribtimine (Kygevvi)O | – | FDA | 2025-11-03 | 2025-11-03 | ||||||||
| 2025 | Elamipretide (Forzinity)O | – | FDA | 2025-09-19 | 2025-09-19 | ||||||||
| 2025 | Elinzanetant (Lynkuet) | – | HC | 2025-07-23 | 2025-10-24 | 2025-11-17 | 2025-07-23 | ||||||
| 2025 | Etripamil (Cardamyst) | – | FDA | 2025-12-12 | 2025-12-12 | ||||||||
| 2025 | Etuvetidigene autotemcel (Waskyra)O | – | FDA | 2025-12-09 | 2025-12-09 | ||||||||
| 2025 | Fitusiran (Qfitlia)O | – | FDA | 2025-03-28 | 2025-03-28 | ||||||||
| 2025 | Garadacimab (Andembry)B,O | – | EMA | 2025-02-10 | 2025-06-16 | 2025-02-10 | 2025-08-06 | ||||||
| 2025 | Gepotidacin (Blu Jepa) | – | FDA | 2025-03-25 | 2025-03-25 | ||||||||
| 2025 | Imlunestrant (Inluri Yo)C | – | FDA | 2025-09-25 | 2025-09-25 | 2026-01-09 | |||||||
| 2025 | Lerodalcibep (Lerochol) | – | FDA | 2025-12-12 | 2025-12-12 | ||||||||
| 2025 | Linvoseltamab (Lynozyfic)B,C,O | – | EMA | 2025-04-23 | 2025-07-02 | 2025-04-23 | |||||||
| 2025 | Meningococcal groups a, b, c, w and y vaccine (Penmenvy)B | – | FDA | 2025-02-14 | 2025-02-14 | ||||||||
| 2025 | Mirdametinib (Gomekli/ezmekly)O | – | FDA | 2025-02-11 | 2025-02-11 | 2025-07-17 | |||||||
| 2025 | Narsoplimab (Yartemlea)B,O | – | FDA | 2025-12-23 | 2025-12-23 | ||||||||
| 2025 | Nerandomilast (Jascayd)O | – | FDA | 2025-10-07 | 2025-10-07 | ||||||||
| 2025 | Nipocalimab (Imaavy)B,O | – | FDA | 2025-04-29 | 2025-04-29 | 2025-11-28 | 2025-12-05 | ||||||
| 2025 | Paltusotine (Palsonify)O | – | FDA | 2025-09-25 | 2025-09-25 | ||||||||
| 2025 | Pembrolizumab and berahyaluronidase alfa (Keytruda Qlex)B,C | – | FDA | 2025-09-19 | 2025-09-19 | ||||||||
| 2025 | Penpulimab (Penpulimab)B,C,O | – | FDA | 2025-04-23 | 2025-04-23 | ||||||||
| 2025 | Plozasiran (Redemplo)O | – | FDA | 2025-11-18 | 2025-11-18 | 2026-01-02 | |||||||
| 2025 | Prademagene zamikeracel (Zevaskyn)B,O | – | FDA | 2025-04-28 | 2025-04-28 | ||||||||
| 2025 | Remibrutinib (Rhapsido) | – | FDA | 2025-09-30 | 2025-09-30 | ||||||||
| 2025 | Revakinagene taroretcel (Encelto)B | – | FDA | 2025-03-05 | 2025-03-05 | ||||||||
| 2025 | Rilzabrutinib (Wayrilz)O | – | FDA | 2025-08-29 | 2025-08-29 | 2025-12-22 | |||||||
| 2025 | Sebetralstat (Ekterly)O | – | FDA | 2025-07-03 | 2025-07-03 | 2025-09-17 | |||||||
| 2025 | Sepiapterin (Sephience)O | – | EMA | 2025-06-19 | 2025-07-28 | 2025-06-19 | 2025-10-07 | ||||||
| 2025 | Sevabertinib (Hyrnuo)C,O | – | FDA | 2025-11-19 | 2025-11-19 | ||||||||
| 2025 | Sibeprenlimab (Voyxact)B | – | FDA | 2025-11-25 | 2025-11-25 | ||||||||
| 2025 | Sunvozertinib (Zegfrovy)C | – | FDA | 2025-07-02 | 2025-07-02 | ||||||||
| 2025 | Suzetrigine (Journavx) | – | FDA | 2025-01-30 | 2025-01-30 | ||||||||
| 2025 | Taletrectinib (Ibtrozi)C,O | – | FDA | 2025-06-11 | 2025-06-11 | ||||||||
| 2025 | Telisotuzumab vedotin (Emrelis)B,C | – | FDA | 2025-05-14 | 2025-05-14 | ||||||||
| 2025 | Tradipitant (Nereus) | – | FDA | 2025-12-30 | 2025-12-30 | ||||||||
| 2025 | Vimseltinib (Romvimza)O | – | FDA | 2025-02-14 | 2025-02-14 | 2025-09-17 | |||||||
| 2025 | Ziftomenib (Komzifti)C,O | – | FDA | 2025-11-13 | 2025-11-13 | ||||||||
| 2025 | Zoliflodacin (Nuzolvence) | – | FDA | 2025-12-12 | 2025-12-12 | ||||||||
| 2025 | Zongertinib (Hernexeos) | – | FDA | 2025-08-08 | 2025-08-08 | ||||||||
| 2025 | Zopapogene imadenovec (Papzimeos)B,O | – | FDA | 2025-08-14 | 2025-08-14 | ||||||||
| 2024 | *RSV f-protein mrna, 5'(M7g-5'-ppp-5'-gm), 3'polya (Mresvia)B | – | FDA | 2024-05-31 | 2024-05-31 | 2024-08-22 | 2024-11-06 | ||||||
| 2024 | Acellular tissue engineered vessel-tyod (Symvess)B | – | FDA | 2024-12-19 | 2024-12-19 | ||||||||
| 2024 | Afamitresgene autoleucel (Tecelra)B,C,O | – | FDA | 2024-08-01 | 2024-08-01 | ||||||||
| 2024 | Arimoclomol (Miplyffa)O | – | FDA | 2024-09-20 | 9/20/2024 | ||||||||
| 2024 | Axatilimab (Niktimvo)B,O | – | FDA | 2024-08-14 | |||||||||
| 2024 | Berdazimer (Zelsuvmi) | – | FDA | 2024-05-01 | |||||||||
| 2024 | Cosibelimab (Unloxcyt)B,C | – | FDA | 2024-12-13 | 12/13/2024 | ||||||||
| 2024 | Crinecerfont (Crenessity)O | – | FDA | 2024-12-13 | 12/13/2024 | ||||||||
| 2024 | Deuruxolitinib (Leqselvi) | – | FDA | 2024-07-25 | 7/25/2024 | ||||||||
| 2024 | Enmetazobactam (Exblifep) | – | FDA | 2024-02-22 | |||||||||
| 2024 | Ensartinib (Ensacove)C | – | FDA | 2024-12-18 | 12/18/2024 | ||||||||
| 2024 | Givinostat (Duvyzat)O | – | FDA | 2024-03-21 | |||||||||
| 2024 | Levacetylleucine (Aqneursea)O | – | FDA | 2024-09-24 | |||||||||
| 2024 | Lifileucel (Amtagvi)B,C,O | – | FDA | 2024-02-16 | 2024-02-16 | 2025-08-15 | |||||||
| 2024 | Mavorixafor (Xolremdi)O | – | FDA | 2024-04-26 | 4/26/2024 | ||||||||
| 2024 | Obecabtagene autoleucel (Aucatzyl)B,C,O | – | FDA | 2024-11-08 | 2024-11-08 | 2025-07-17 | |||||||
| 2024 | Odronextamab (Ordspono)B,C,O | – | EMA | 2024-08-22 | 22/08/2024 | ||||||||
| 2024 | Olezarsen (Tryngolza)O | – | FDA | 2024-12-19 | 12/19/2024 | ||||||||
| 2024 | Pegulicianine (Lumisight)C | – | FDA | 2024-04-17 | 4/17/2024 | ||||||||
| 2024 | Remestemcel-l (Ryoncil)B | – | FDA | 2024-12-18 | 2024-12-18 | ||||||||
| 2024 | Sugemalimab (Cejemly)B,C | – | EMA | 2024-07-24 | 24/07/2024 | ||||||||
| 2024 | Sulopenem etzadroxil, probenecid (Orlynvah) | – | FDA | 2024-10-25 | 10/25/2024 | ||||||||
| 2024 | Vanzacaftor, tezacaftor, and deutivacaftor (Alyftrek)O | – | FDA | 2024-12-20 | 12/20/2024 | 2025-06-30 | |||||||
| 2024 | Xanomeline and trospium chloride (Cobenfy) | – | FDA | 2024-09-26 | 9/26/2024 | ||||||||
| 2024 | Zanidatamab (Ziihera)B,C,O | – | FDA | 2024-11-20 | 11/20/2024 | 2025-04-25 | |||||||
| 2024 | Zenocutuzumab (Bizengri)B,C,O | – | FDA | 2024-12-04 | |||||||||
| 2023 | Donislecel (Lantidra)B,O | – | FDA | 2023-06-28 | 06/28/2023 | ||||||||
| 2023 | Durlobactam (Xacduro) | – | FDA | 2023-05-23 | 5/23/2023 | ||||||||
| 2023 | Elacestrant (Orserdu)C | – | FDA | 2023-01-27 | 1/27/2023 | 2023-09-15 | |||||||
| 2023 | Exagamglogene autotemcel (Casgevy)B,O | – | FDA | 2023-12-08 | 12/08/2023 | 2024-02-09 | 2024-09-23 | ||||||
| 2023 | Fidanacogene elaparvovec (Beqvez)B,O | – | HC | 2023-12-27 | 04/25/24 | 2024-07-24 | 2023-12-27 | ||||||
| 2023 | Gepirone (Exxua) | – | FDA | 2023-09-22 | 9/22/2023 | ||||||||
| 2023 | Leniolisib (Joenja)O | – | FDA | 2023-03-24 | |||||||||
| 2023 | Lovotibeglogene autoleucel (Lyfgenia)B,O | – | FDA | 2023-12-08 | 12/08/2023 | ||||||||
| 2023 | Omidubicel (Omiserge)B,O | – | FDA | 2023-04-17 | 04/17/2023 | ||||||||
| 2023 | Pozelimab (Veopoz)B,O | – | FDA | 2023-08-18 | 8/18/2023 | ||||||||
| 2023 | Trofinetide (Daybue)O | – | FDA | 2023-03-10 | 3/10/2023 | 2024-10-11 | |||||||
| 2022 | Daxibotulinumtoxin a (Daxxify)B | – | FDA | 2022-09-07 | 2022-09-07 | ||||||||
| 2022 | Etranacogene dezaparvovec (Hemgenix)B,O | – | FDA | 2022-11-22 | |||||||||
| 2022 | Lutetium (177Lu) vipivotide tetraxetan (Pluvicto)C | – | FDA | 2022-03-23 | 2022-03-23 | 2022-12-09 | 2022-08-25 | ||||||
| 2022 | Mitapivat (Pyrukynd)O | – | FDA | 2022-02-09 | |||||||||
| 2022 | Vaccine, SARS-CoV-2 (Valneva)B | – | EMA | 2022-06-24 | 2022-06-24 | ||||||||
| 2022 | Vaccine, SARS-CoV-2 subunit (Nuvaxovid)B | – | EMA | 2022-11-11 | |||||||||
| 2022 | Virus-like particles (Vlp) of SARS-CoV-2 spike protein (Covifenz) | – | FDA | 2022-02-24 | 2022-02-24 | ||||||||
| 2021 | Allogeneic processed thymus tissue (Rethymic)B | – | FDA | 2021-10-08 | 2021-10-08 | ||||||||
| 2021 | Efgartigimod (Vyvgart)B | – | FDA | 2021-12-17 | 2021-12-17 | 2023-08-10 | 2023-09-19 | ||||||
| 2021 | Fexinidazole (Fexinidazole)O | – | FDA | 2021-07-16 | 2021-07-16 | ||||||||
| 2021 | Fosdenopterin (Nulibry)O | – | FDA | 2021-02-26 | 2021-02-26 | 2022-09-21 | |||||||
| 2021 | Pafolacianine (Cytalux)C | – | FDA | 2021-11-29 | 2021-11-29 | ||||||||
| 2021 | Regdanvimab (Regkirona)B | – | EMA | 2021-11-12 | |||||||||
| 2021 | Sotrovimab (Xevudy)B | – | EMA | 2021-12-17 | 2021-12-17 | ||||||||
| 2021 | Umbralisib (Ukon iq)C,O | – | FDA | 2021-02-05 | |||||||||
| 2021 | Vaccine, SARS-CoV-2 non-replicating vector (Vaxzevria)B | – | HC | 2022-02-20 | |||||||||
Note: A medicine was considered to be new in 2022 if it received initial market authorization through the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and/or Health Canada during the calendar year. Availability and sales information refer to all forms and strengths of the medicine, while pricing and treatment costs are based on the highest-selling form and strength indicated. Sales are based on manufacturer list prices. Specialty medicines are indicated using the following abbreviations: B: biologic; C: cancer; G: gene therapy; O: orphan. * Level 2 of the Anatomical Classification of Pharmaceutical Products, as reported in MIDAS ®, except for the new medicines without sales data in MIDAS®, for which the reporting is based on the Anatomic Therapeutic Chemical (ATC) Classification System maintained by the World Health Organization (WHO). § Treatment costs were taken from CDA-AMC Reimbursement Review reports where available; otherwise, they were calculated using Canadian list prices if available or, if no other countries reported sales, the US price was used. Information on dosing regimens was taken from the product monograph provided by Health Canada, or the FDA or EMA if unavailable though Health Canada. Data source: IQVIA MIDAS® Database, 2025 (all rights reserved); US Food and Drug Administration Novel Drugs; European Medicines Agency Human Medicines Highlights; Health Canada. | |||||||||||||
Data supplement B: New Canadian Medicines with sales 2021–2025
Data supplement B: New Canadian Medicines with sales 2021–2025
| Approval cohort | Medicine (trade name, form, strength, volume) | ATC2 | Notice of Complicance (NOC) date | first sale oecd | first sale Canada | first sale USA | No. of months from OECD to Canadian sale | No. of months from international to Canadian sale | Share of Cdn new med sales | Number of OECD countries with sales* | OECD MINIMUM PRICE | OECD MAXIMUM PRICE | Canadian price relative to midpoint of range |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | Abrocitinib (Cibinqo, abc film-ctd tabs, 200 mg, NA vol) | D5 Nonsteroidal products for inflammatory skin disorders | – | 2021-10-01 | 2022-09-01 | 2022-03-01 | 11 | 11 | 0.42% | 25 | $ 16.14 | $ 46.75 | Above |
| 2023 | Amifampridine (Firdapse, aaa tablets, 10 mg, NA vol)O | M5 Musculo-skeletal system | – | 2009-12-01 | 2021-07-01 | 2020-01-01 | 139 | 139 | 0.01% | 19 | $ 20.90 | $ 27.23 | Below |
| 2022 | Amivantamab (Rybrevant, fqc infus.via/bot., 50 mg/1 ml, 7ml)B,C | L1 Antineoplastics | – | 2021-06-01 | 2022-04-01 | 2021-06-01 | 10 | 10 | 0.25% | 16 | $ 1,163.07 | $ 1,945.66 | Above |
| 2023 | Andexanet alfa (Ondexxya, fpb vial dry, 200 mg, NA vol)B,O | B2 Blood coagulation system products | – | 2018-06-01 | – | 2018-06-01 | – | – | 0.00% | 15 | $ 2,461.67 | $ 4,345.09 | NA |
| 2021 | Anifrolumab (Saphnelo, fqc infus.via/bot., 75 mg/1 ml, 2 ml)B | L4 Immunosuppressants | – | 2021-07-01 | 2022-03-01 | 2021-08-01 | 8 | 8 | 0.39% | 20 | $ 698.47 | $ 6,673.40 | Below |
| 2022 | Asciminib (Scemblix, abc film-ctd tabs, 40 mg, NA vol)C,O | L1 Antineoplastics | – | 2021-11-01 | 2022-09-01 | 2021-11-01 | 10 | 10 | 1.26% | 25 | $ 62.61 | $ 100.64 | Near |
| 2022 | Atogepant (Qulipta, aaa tablets, 60 mg, NA vol) | N2 Analgesics | – | 2021-10-01 | 2023-02-01 | 2021-10-01 | 16 | 16 | 1.33% | 18 | $ 7.46 | $ 18.15 | Above |
| 2022 | Avacopan (Tavneos, aca capsules, 10 mg, NA vol)O | C6 Other cardiovascular products | – | 2021-10-01 | 2022-11-01 | 2021-10-01 | 13 | 13 | 0.56% | 17 | $ 10.20 | $ 44.24 | Above |
| 2021 | Avalglucosidase alfa (Nexviazyme, fqd inf dry bottle, 100 mg, NA vol)B,O | A16 Other alimentary tract and metabolism products | – | 2021-09-01 | 2022-02-01 | 2021-09-01 | 5 | 5 | 0.36% | 15 | $ 1,041.01 | $ 1,566.18 | Above |
| 2024 | Avapritinib (Ayvakit, abc film-ctd tabs, 25 mg, NA vol)C,O | L1 Antineoplastics | – | 2020-01-01 | 2025-03-01 | 2020-01-01 | 62 | 62 | 0.00% | 11 | $ 681.93 | $ 911.82 | NA |
| 2023 | Avatrombopag (Doptelet, abc film-ctd tabs, 20 mg, NA vol)O | B2 Blood coagulation system products | – | 2018-06-01 | 2024-05-01 | 2018-06-01 | 71 | 71 | 0.03% | 23 | $ 51.65 | $ 82.20 | Above |
| 2022 | Belzutifan (Welireg, abc film-ctd tabs, 40 mg, NA vol)C,O | L1 Antineoplastics | – | 2021-09-01 | 2022-08-01 | 2021-09-01 | 11 | 11 | 0.56% | 5 | $ 206.28 | $ 223.95 | Below |
| 2022 | Berotralstat (Orladeyo, aca capsules, 150 mg, NA vol)O | B6 All other haematological agents | – | 2021-03-01 | – | – | – | – | 0.00% | 15 | $ 487.57 | $ 586.40 | NA |
| 2022 | Bimekizumab (Bimzelx, fnh prefil autoinj, 160 mg/1 ml, 1ml)B | L4 Immunosuppressants | – | 2021-08-01 | 2022-03-01 | 2023-11-01 | 7 | 7 | 3.76% | 25 | $ 336.46 | $ 1,184.70 | Above |
| 2021 | Binimetinib (Mektovi, abc film-ctd tabs, 15 mg, NA vol)C,O | L1 Antineoplastics | – | 2018-07-01 | 2021-11-01 | 2018-07-01 | 40 | 40 | 0.71% | 23 | $ 18.74 | $ 37.82 | Above |
| 2021 | Brexucabtagene autoleucel (Tecartus, fqe infusion bags, na intstr, NA vol)B,C,G,O | L1 Antineoplastics | – | 2020-12-01 | 2021-12-01 | – | 12 | 12 | 2.23% | 9 | $ 404,553.95 | $ 569,660.21 | Above |
| 2021 | Brilliant blue g (Tissueblue, nna p-f syr ophth, 250 y/1 ml, 0.5ml)O | S1 Ophthalmologicals | – | 2020-06-01 | – | 2020-06-01 | – | – | 0.00% | 1 | – | – | NA |
| 2023 | Calaspargase pegol (Asparlas, fqc infus.via/bot., 750 iu/1 ml, 5 ml)B,C,O | L1 Antineoplastics | – | 2021-08-01 | – | 2021-08-01 | – | – | 0.00% | 1 | – | – | NA |
| 2023 | Cangrelor (Kengreal, fpb vial dry, 50 mg, NA vol) | B1 Antithrombotic agents | – | 2015-03-01 | – | 2015-07-01 | – | – | 0.00% | 17 | $ 126.91 | $ 444.33 | NA |
| 2024 | Capivasertib (Truqap, abc film-ctd tabs, 200 mg, NA vol)C | L1 Antineoplastics | – | 2023-12-01 | 2024-04-01 | 2023-12-01 | 4 | 4 | 0.59% | 10 | $ 81.73 | $ 142.43 | Above |
| 2022 | Capmatinib (Tabrecta, abc film-ctd tabs, 200 mg, NA vol)C,O | L1 Antineoplastics | – | 2020-05-01 | 2022-09-01 | 2020-05-01 | 28 | 28 | 0.05% | 16 | $ 29.88 | $ 81.42 | Above |
| 2022 | Cariprazine (Vraylar, aca capsules, 1.5 mg, NA vol) | N5 Psycholeptics | – | 2016-03-01 | 2022-06-01 | 2016-03-01 | 75 | 75 | 0.54% | 24 | $ 1.22 | $ 2.72 | Above |
| 2023 | Cenobamate (Xcopri, abc film-ctd tabs, 200 mg, NA vol) | N3 Anti-epileptics | – | 2020-05-01 | 2023-12-01 | 2020-05-01 | 43 | 43 | 0.17% | 23 | $ 2.67 | $ 51.34 | Below |
| 2023 | Ciltacabtagene autoleucel (Carvykti, fqe infusion bags, na intstr, NA vol)B,C,O | L1 Antineoplastics | – | 2023-02-01 | – | – | – | – | 0.00% | 1 | $ 425,106.00 | $ 425,106.00 | NA |
| 2023 | Clascoterone (Winlevi, mta cream, 1 %, 30 g) | D10 Anti-acane preparations | – | 2021-10-01 | 2023-09-01 | 2021-10-01 | 23 | 23 | 0.81% | 3 | – | – | NA |
| 2023 | Concizumab (Alhemo, frf p-f pens, 100 mg/1 ml, NA vol)B,O | B2 Blood coagulation system products | – | 2023-11-01 | – | 2025-02-01 | – | – | 0.00% | 1 | $ 13,759.55 | $ 13,759.55 | NA |
| 2024 | Danicopan (Voydeya, abc film-ctd tabs, NA intstr, NA vol)O | B6 All other haematological agents | – | 2024-06-01 | – | – | – | – | 0.00% | 1 | $ 56.10 | $ 56.10 | NA |
| 2023 | Daridorexant (Quviviq, abc film-ctd tabs, 50 mg, NA vol) | N5 Psycholeptics | – | 2022-04-01 | 2023-07-01 | 2022-04-01 | 15 | 15 | 0.24% | 12 | $ 0.66 | $ 3.15 | Above |
| 2022 | Deucravacitinib (Sotyktu, abc film-ctd tabs, 6 mg, NA vol) | D5 Nonsteroidal products for inflammatory skin disorders | – | 2022-09-01 | 2023-07-01 | 2022-09-01 | 10 | 10 | 0.23% | 18 | $ 13.44 | $ 36.67 | Above |
| 2022 | Difelikefalin (Korsuva, fnc p-f syrng i.v., 35.7 y/1 ml, 0.7 ml) | D4 Anti-pruritics | – | 2022-04-01 | 2023-02-01 | 2022-05-01 | 10 | 10 | 0.02% | 14 | $ 26.23 | $ 26.23 | NA |
| 2021 | Dostarlimab (Jemperli, fqc infus.via/bot., 50 mg/1 ml, 10 ml)B,C | L1 Antineoplastics | – | 2020-11-01 | 2022-06-01 | 2021-05-01 | 19 | 19 | 0.09% | 17 | $ 3,527.50 | $ 8,376.42 | Above |
| 2023 | Efgartigimod alfa (Vyvgart, fqc infus.via/bot., 20 mg/1 ml, NA vol)B,O | M5 Musculo-skeletal system | – | 2022-01-01 | – | 2022-01-01 | – | – | 0.00% | 14 | $ 5,828.67 | $ 11,527.46 | NA |
| 2021 | Elexacaftor (Trikafta, abc film-ctd tabs, 100 mg+75 mg+50 mg, NA vol)O | R7 Other respiratory system products | – | 2019-10-01 | – | 2019-10-01 | – | – | 0.00% | 21 | $ 209.48 | $ 234.47 | NA |
| 2023 | Elranatamab (Elrexfio, fpe vial sc, 40 mg/1 ml, 1.9 ml)B,C,O | L1 Antineoplastics | – | 2023-03-01 | 2024-03-01 | 2023-09-01 | 12 | 6 | 0.02% | 14 | $ 5,630.70 | $ 7,487.67 | Above |
| 2021 | Encorafenib (Braftovi, aca capsules, 75 mg, NA vol)C,O | L1 Antineoplastics | – | 2018-07-01 | 2021-11-01 | 2018-07-01 | 40 | 40 | 1.24% | 25 | $ 30.80 | $ 45.09 | Above |
| 2021 | Enfortumab vedotin (Padcev, fqd inf dry bottle, 20 mg, NA vol)B,C | L1 Antineoplastics | – | 2019-12-01 | 2022-06-01 | 2019-12-01 | 30 | 30 | 1.65% | 22 | $ 445.39 | $ 898.52 | Above |
| 2023 | Epcoritamab (Epkinly, fpe vial sc, 60 mg/1 ml, 0.8 ml)B,C,O | L1 Antineoplastics | – | 2023-09-01 | 2023-12-01 | 2023-11-01 | 3 | 3 | 0.43% | 12 | $ 11,596.07 | $ 11,596.07 | NA |
| 2024 | Eplontersen (Wainua, fnh prefil autoinj, 56.3 mg/1 ml, 0.8 ml)O | N7 Other central nervous system drugs | – | 2024-01-01 | 2024-10-01 | 2024-01-01 | 9 | 9 | 0.20% | 2 | – | – | NA |
| 2021 | Eptinezumab (Vyepti, fqc infus.via/bot., 100 mg/1 ml, 1 ml)B | N2 Analgesics | – | 2020-03-01 | 2022-11-01 | 2020-03-01 | 32 | 32 | 2.04% | 21 | $ 704.94 | $ 1,322.51 | Above |
| 2023 | Etranacogene dezaparvovec (Hemgenix, fqc infus.via/bot., NA intstr, 10 ml)B,O | B2 Blood coagulation system products | – | 2023-05-01 | 2024-05-01 | – | – | 0.00% | 0 | – | – | NA | |
| 2024 | Etrasimod (Velsipity, abc film-ctd tabs, 2 mg, NA vol) | A7 Intestinal disorder products | – | 2023-12-01 | 2024-04-01 | 2023-12-01 | 4 | 4 | 0.02% | 12 | $ 31.74 | $ 43.92 | Above |
| 2023 | Evinacumab (Evkeeza, fqc infus.via/bot., 150 mg/1 ml, 2.3 ml)B,O | C10 Lipid-regulating/anti-atheroma preparations | – | 2021-05-01 | 2021-05-01 | – | – | 0.00% | 8 | $ 1,846.28 | $ 10,410.26 | NA | |
| 2022 | Faricimab (Vabysmo, npa ophthal vials, 120 mg/1 ml, 0.24 ml)B | S1 Ophthalmologicals | – | 2022-02-01 | 2022-07-01 | 2022-02-01 | 5 | 5 | 9.65% | 27 | $ 608.15 | $ 1,058.23 | Above |
| 2024 | Fezolinetant (Veoza h, abc film-ctd tabs, 45 mg, NA vol) | G2 Other gynaecologicals | – | 2023-05-01 | 2025-03-01 | 2023-05-01 | 22 | 22 | 0.00% | 14 | $ 1.74 | $ 2.55 | NA |
| 2022 | Finerenone (Kerendia, abc film-ctd tabs, 10 mg, NA vol) | C3 Diuretics | – | 2021-07-01 | 2022-11-01 | 2021-07-01 | 16 | 16 | 1.00% | 28 | $ 1.05 | $ 2.40 | Above |
| 2024 | Fruquintinib (Fruzaqla, aca capsules, 5 mg, NA vol)C | L1 Antineoplastics | – | 2023-11-01 | 2025-04-01 | 2023-11-01 | 17 | 17 | 0.00% | 10 | $ 173.48 | $ 295.85 | NA |
| 2023 | Gallium ga 68 gozetotide (Locametz, fpb vial dry, 25 y, NA vol) | T1 Diagnostic imaging | – | 2022-09-01 | – | – | – | – | 0.00% | 4 | $ 1,227.17 | $ 2,001.39 | NA |
| 2023 | Glofitamab (Columvi, fqc infus.via/bot., 1 mg/1 ml, 10 ml)B,C,O | L1 Antineoplastics | – | 2021-04-01 | 2023-08-01 | 2023-06-01 | 28 | 2 | 0.24% | 15 | $ 4,310.79 | $ 4,650.20 | Below |
| 2021 | Idecabtagene vicleucel (Abecma, fqe infusion bags, NA intstr, 50 ml)B,C,O | L1 Antineoplastics | – | 2021-05-01 | – | – | – | – | 0.00% | 4 | $ 402,285.41 | $ 402,285.41 | NA |
| 2021 | Inclisiran (Leqvio, fne p-f syrng sc, 189 mg/1 ml, 1.5 ml) | C10 Lipid-regulating/anti-atheroma preparations | – | 2020-12-01 | 2022-09-01 | 2022-01-01 | 21 | 21 | 0.76% | 24 | $ 896.56 | $ 2,877.85 | Above |
| 2023 | Inebilizumab (Uplizna, fqc infus.via/bot., 10 mg/1 ml, 10 ml)B,O | N7 Other central nervous system drugs | – | 2020-12-01 | – | 2021-04-01 | – | – | 0.00% | 8 | $ 22,657.58 | $ 26,196.69 | NA |
| 2021 | Infigratinib (Truseltiq, aca capsules, vari str, NA vol)C,O | L1 Antineoplastics | – | 2021-07-01 | – | 2021-07-01 | – | – | 0.00% | 0 | – | – | NA |
| 2024 | Insulin icodec (Awiqli, grf p-f pens ret, 700 iu/1 ml, 3 ml)B | A10 Drugs used in diabetes | – | 2024-09-01 | 2024-06-01 | – | 3 | 3 | 0.12% | 2 | $ 147.16 | $ 147.16 | Above |
| 2024 | Iron ferric (Venofer, fpc vial IV, 20 mg/1 ml, 5 ml) | B3 Haematinics, iron and all combinations | – | 1945-01-01 | 2001-05-01 | 1975-10-01 | 676 | 676 | 6.91% | 31 | $ 2.82 | $ 16.06 | Above |
| 2024 | Ivosidenib (Tibsovo, abc film-ctd tabs, 250 mg, NA vol)C,O | L1 Antineoplastics | – | 2018-08-01 | – | 2018-08-01 | – | – | 0.00% | 13 | $ 247.24 | $ 328.34 | NA |
| 2023 | Landiolol (Corebeta, fqd inf dry bottle, 50 mg, NA vol) | C7 Beta-blocking agents | – | 2002-09-01 | – | – | – | – | 0.00% | 14 | $ 29.74 | $ 29.74 | NA |
| 2024 | Lebrikizumab (Ebglyss, fnh prefil autoinj, 125 mg/1 ml, 2 ml)B | D5 Nonsteroidal products for inflammatory skin disorders | – | 2023-11-01 | 2024-09-01 | 2024-10-01 | 10 | 10 | 0.02% | 11 | $ 389.75 | $ 1,432.30 | Above |
| 2022 | Lenacapavir (Sunlenca, abc film-ctd tabs, 300 mg, NA vol) | J5 Antivirals for systemic use | – | 2022-08-01 | 2023-03-01 | 2023-01-01 | 7 | 7 | 0.00% | 11 | $ 759.59 | $ 895.24 | Above |
| 2022 | Lisocabtagene maraleucel (Breyanzi, fqc infus.via/bot., NA intstr, NA vol)B,C,G,O | L1 Antineoplastics | – | 2021-05-01 | – | – | – | – | 0.00% | 3 | $ 237,303.81 | $ 292,982.65 | NA |
| 2022 | Lumasiran (Ox lumo, fpe vial sc, 189 mg/1 ml, 0.5 ml)O | G4 Urologicals | – | 2021-01-01 | – | 2021-02-01 | – | – | 0.00% | 10 | $ 63,557.08 | $ 91,410.41 | NA |
| 2021 | Lurbinectedin (Zepzelca, fqd inf dry bottle, 4 mg, NA vol)C,O | L1 Antineoplastics | – | 2020-09-01 | – | 2020-09-01 | – | – | 0.00% | 3 | $ 4,547.26 | $ 5,716.75 | NA |
| 2022 | Lutetium (177lu) vipivotide tetraxetan (Pluvicto, fpc vial IV, NA intstr, 30 ml)C | V3 All other therapeutic products | – | 2023-01-01 | 2024-03-01 | 2025-02-01 | 14 | 8 | 0.06% | 6 | $ 23,019.27 | $ 31,824.45 | Near |
| 2023 | Maralixibat (Livmarli, dga oral liquid, 47.5 mg/5 ml, 30 ml)O | A5 Cholagogues and hepatic protectors | – | 2023-01-01 | – | – | – | – | 0.00% | 10 | $ 5,748.38 | $ 7,357.66 | NA |
| 2022 | Maribavir (Livtencity, abc film-ctd tabs, 200 mg, NA vol)O | J5 Antivirals for systemic use | – | 2021-12-01 | 2023-01-01 | 2021-12-01 | 13 | 13 | 0.53% | 20 | $ 3.62 | $ 283.00 | Above |
| 2022 | Mavacamten (Camzyos, aca capsules, 5 mg, NA vol)O | C1 Cardiac therapy | – | 2022-06-01 | 2023-08-01 | 2022-06-01 | 14 | 14 | 0.51% | 17 | $ 53.52 | $ 73.51 | Near |
| 2024 | Metreleptin (Myalept, fpb vial dry, 11.3 mg, NA vol)B,O | A16 Other alimentary tract and metabolism products | – | 2013-07-01 | – | 2014-06-01 | – | – | 0.00% | 11 | $ 2,444.29 | $ 2,444.29 | NA |
| 2023 | Mirikizumab (Omvoh, fnh prefil autoinj, 100 mg/1 ml, 1 ml)B,O | A7 Intestinal disorder products | – | 2023-05-01 | 2023-10-01 | 2023-11-01 | 5 | 5 | 0.13% | 16 | $ 339.39 | $ 906.07 | Above |
| 2022 | Mogamulizumab (Poteligeo, fqc infus.via/bot., 4 mg/1 ml, 5 ml)B,O | L1 Antineoplastics | – | 2012-05-01 | – | 2018-10-01 | – | – | 0.00% | 17 | $ 1,244.53 | $ 1,840.05 | NA |
| 2024 | Momelotinib (Ojjaara, abc film-ctd tabs, 200 mg, NA vol)C,O | L1 Antineoplastics | – | 2023-04-01 | 2025-01-01 | 2023-09-01 | 21 | 21 | 0.00% | 8 | $ 135.21 | $ 227.42 | NA |
| 2022 | Nirmatrelvir (Paxlovid, abc film-ctd tabs, 150 mg + 100 mg, NA vol) | J5 Antivirals for systemic use | – | 2021-12-01 | 2022-01-01 | 2021-12-01 | 1 | 1 | 6.02% | 29 | $ 23.18 | $ 41.35 | Above |
| 2023 | Nirsevimab (Beyfortus, fnd pre-fill i.m, 100 mg/1 ml, 1 ml)B | J6 Sera and gamma-globulin | – | 2023-09-01 | – | 2023-09-01 | – | – | 0.00% | 10 | $ 320.97 | $ 748.48 | NA |
| 2023 | Odevixibat (Bylvay, aca capsules, 1.2 mg, NA vol)O | A5 Cholagogues and hepatic protectors | – | 2021-07-01 | 2025-04-01 | – | 45 | 45 | 0.00% | 12 | $ 609.31 | $ 901.37 | NA |
| 2024 | Olipudase alfa (Xenpozyme, fqd inf dry bottle, 20 mg, NA vol)B,O | A16 Other alimentary tract and metabolism products | – | 2021-11-01 | – | 2022-09-01 | – | – | 0.00% | 12 | $ 4,111.90 | $ 4,774.50 | NA |
| 2021 | Ospemifene (Osphena, abc film-ctd tabs, 60 mg, NA vol) | G3 Sex hormones and products with similar desired effects, systemic action only | – | 2013-05-01 | 2022-01-01 | 2013-05-01 | 104 | 104 | 0.03% | 5 | $ 1.45 | $ 10.65 | Below |
| 2022 | Palovarotene (Sohonos, aca capsules, 5mg, NA vol)O | M5 Musculo-skeletal system | – | 2023-11-01 | – | 2023-11-01 | – | – | 0.00% | 1 | – | – | NA |
| 2022 | Pegcetacoplan (Aspaveli, fqc infus.via/bot., 54mg/1ml, 20ml)O | B6 All other haematological agents | – | 2021-07-01 | – | 2021-07-01 | – | – | 0.00% | 15 | $ 2,956.89 | $ 4,508.20 | NA |
| 2022 | Pegvaliase (Palynziq, fne p-f syrng sc, 20mg/1ml, 1ml)B,O | A16 Other alimentary tract and metabolism products | – | 2018-07-01 | – | 2018-07-01 | – | – | 0.00% | 5 | $ 398.45 | $ 475.86 | NA |
| 2021 | Pemigatinib (Pemazyre, aaa tablets, 13.5 mg, NA vol)C,O | L1 Antineoplastics | – | 2020-05-01 | – | 2020-05-01 | – | – | 0.00% | 18 | $ 0.11 | $ 722.31 | NA |
| 2024 | Perfluorohexyloctane (Miebo, ngb drops eye, 100 %, 3 ml) | S1 Ophthalmologicals | – | 2023-09-01 | – | 2023-09-01 | – | – | 0.00% | 1 | – | – | NA |
| 2021 | Pitolisant (Wakix, abc film-ctd tabs, 20 mg, NA vol)O | N7 Other central nervous system drugs | – | 2016-03-01 | 2022-01-01 | 2019-11-01 | 70 | 70 | 0.13% | 18 | $ 2.05 | $ 14.58 | Above |
| 2021 | Ponesimod (Ponvory, abc film-ctd tabs, 20 mg, NA vol) | N7 Other central nervous system drugs | – | 2021-04-01 | – | 2021-04-01 | – | – | 0.00% | 21 | $ 32.38 | $ 46.87 | NA |
| 2021 | Pralsetinib (Gavreto, aca capsules, 100 mg, NA vol)C,O | L1 Antineoplastics | – | 2020-11-01 | 2022-03-01 | 2020-11-01 | 16 | 16 | 0.02% | 14 | $ 40.17 | $ 57.00 | Above |
| 2023 | Relatlimab (Opdualag, fqc infus.via/bot., 12 mg/1 ml + 4 mg/1 ml, 20 ml)B,C,O | L1 Antineoplastics | – | 2022-03-01 | 2024-02-01 | 2022-03-01 | 23 | 23 | 0.54% | 11 | $ 8,277.99 | $ 9,058.55 | Below |
| 2023 | Relugolix (Orgovyx, abc film-ctd tabs, 120 mg, NA vol) | L2 Cytostatic hormone therapy | – | 2019-03-01 | 2024-02-01 | 2021-01-01 | 59 | 59 | 0.46% | 26 | $ 3.55 | $ 6.66 | Above |
| 2023 | Rimegepant (Nurtec, aab or disintg tab, 75 mg, NA vol) | N2 Analgesics | – | 2020-03-01 | 2024-03-01 | 2020-03-01 | 48 | 48 | 0.23% | 26 | $ 11.20 | $ 17.78 | Above |
| 2021 | Risdiplam (Evrysdi, dgj dry syrup/drop, 3.75 mg/5 ml, NA vol)O | M5 Musculo-skeletal system | – | 2020-09-01 | 2021-06-01 | 2020-09-01 | 9 | 9 | 2.95% | 22 | $ 739.37 | $ 739.37 | Above |
| 2023 | Ritlecitinib (Litfulo, aca capsules, 50 mg, NA vol) | D5 Nonsteroidal products for inflammatory skin disorders | – | 2023-07-01 | 2024-02-01 | 2023-07-01 | 7 | 7 | 0.07% | 16 | $ 1.31 | $ 39.86 | Above |
| 2021 | Sacituzumab govitecan (Trodelvy, fqd inf dry bottle, 180 mg, NA vol)B,C | L1 Antineoplastics | – | 2020-04-01 | 2021-11-01 | 2020-04-01 | 19 | 19 | 1.38% | 24 | $ 491.08 | $ 1,402.41 | Above |
| 2024 | Segesterone acetate (Annovera, tyq mech pes w sub, 10 y + 150 y, NA vol) | G3 Sex hormones and products with similar desired effects, systemic action only | – | 2019-09-01 | – | 2019-09-01 | – | – | 0.00% | 1 | – | – | NA |
| 2022 | Selinexor (Nexpovio, abc film-ctd tabs, 20 mg, NA vol)C,O | L1 Antineoplastics | – | 2019-07-01 | – | 2019-07-01 | – | – | 0.00% | 8 | $ 219.31 | $ 398.13 | NA |
| 2021 | Selpercatinib (Retevmo, aca capsules, 80 mg, NA vol)C,O | L1 Antineoplastics | – | 2020-05-01 | 2022-01-01 | 2020-05-01 | 20 | 20 | 1.10% | 22 | $ 36.67 | $ 101.34 | Above |
| 2022 | Selumetinib (Koselugo, aca capsules, 10 mg, NA vol) | L1 Antineoplastics | – | 2018-05-01 | 2023-01-01 | 2020-04-01 | 56 | 33 | 0.48% | 21 | $ 82.26 | $ 110.67 | Above |
| 2023 | Setmelanotide (Imcivree, fpe vial sc, 10 mg/1 ml, 1ml)O | A8 Antiobesity preparations, excluding dietetics | – | 2021-07-01 | 2023-07-01 | 24 | 24 | 0.16% | 8 | $ 1,835.12 | $ 3,913.08 | Above | |
| 2021 | Solriamfetol (Sunosi, abc film-ctd tabs, 150 mg, NA vol)O | N7 Other central nervous system drugs | – | 2019-06-01 | 2021-08-01 | 2019-06-01 | 26 | 26 | 0.27% | 13 | $ 11.57 | $ 15.47 | Above |
| 2023 | Somapacitan (Sogroya, frf p-f pens, 10 mg/1 ml, 1.5 ml)B | H4 Other hormones | – | 2021-12-01 | 2023-06-01 | 0.00% | 6 | $ 557.89 | $ 1,189.16 | NA | |||
| 2021 | Somatrogon (Ngenla, frf p-f pens, 50 mg/1 ml, 1.2 ml)B,O | H4 Other hormones | – | 2022-02-01 | 2022-02-01 | 2023-09-01 | 0 | 0 | 0.08% | 24 | $ 207.80 | $ 650.71 | Above |
| 2024 | Sotatercept (Winrevair, fpb vial dry, 45 mg, NA vol)B,O | C6 Other cardiovascular products | – | 2024-06-01 | 2025-02-01 | 2024-06-01 | 8 | 8 | 0.00% | 5 | $ 9,417.64 | $ 9,495.15 | NA |
| 2021 | Sotorasib (Lumakras, abc film-ctd tabs, 120 mg, NA vol)C,O | L1 Antineoplastics | – | 2021-06-01 | 2021-10-01 | 2021-06-01 | 4 | 4 | 0.68% | 24 | $ 22.76 | $ 40.17 | Above |
| 2023 | Spesolimab (Spevigo, fqc infus.via/bot., 60 mg/1 ml, 7.5ml)B,O | D5 Nonsteroidal products for inflammatory skin disorders | – | 2022-09-01 | 2023-05-01 | 2022-09-01 | 8 | 8 | 0.00% | 9 | $ 11,751.22 | NA | |
| 2021 | Tafasitamab (Monjuvi, fqd inf dry bottle, 200 mg, NA vol)B,C,O | L1 Antineoplastics | – | 2020-08-01 | – | 2020-08-01 | – | – | 0.00% | 13 | $ 238.88 | $ 1,628.36 | NA |
| 2024 | Talquetamab (Talvey, fpe vial sc, 40 mg/1 ml, 1 ml)B,C,O | L1 Antineoplastics | – | 2023-08-01 | – | 2023-08-01 | – | – | 0.00% | 13 | $ 6,548.78 | $ 7,568.90 | NA |
| 2024 | Tarlatamab (Imdelltra, fqd inf dry bottle, 10 mg, NA vol)B,C,O | L1 Antineoplastics | – | 2024-05-01 | 2024-11-01 | 2024-05-01 | 6 | 6 | 0.00% | 1 | – | – | NA |
| 2022 | Tebentafusp (Kimmtrak, fqc infus.via/bot., 200 y/1 ml, 0.5 ml)B,C,O | L1 Antineoplastics | – | 2022-02-01 | 2023-12-01 | 2022-02-01 | 22 | 22 | 0.78% | 16 | $ 4,188.41 | $ 16,130.37 | Above |
| 2023 | Teclistamab (Tecvayli, fpe vial sc, 90 mg/1 ml, 1.7 ml)B,C,O | L1 Antineoplastics | – | 2022-08-01 | 2025-05-01 | 2022-11-01 | 33 | 32 | 0.00% | 17 | $ 3,220.11 | $ 6,491.57 | NA |
| 2021 | Tecovirimat (Tecovirimat siga, aca capsules, 200 mg, NA vol)O | J5 Antivirals for systemic use | – | 2022-08-01 | – | – | – | – | 0.00% | 1 | $ 16.96 | $ 16.96 | NA |
| 2021 | Tepotinib (Tepmetko, abc film-ctd tabs, 225 mg, NA vol)C,O | L1 Antineoplastics | – | 2020-06-01 | 2021-11-01 | 2021-02-01 | 17 | 17 | 0.19% | 16 | $ 79.24 | $ 187.92 | Above |
| 2022 | Tezepelumab (Tezspire, fnh prefil autoinj, 110 mg/1 ml, 1.91 ml)B | R3 Anti-asthma and COPD products | – | 2022-01-01 | 2022-10-01 | 2022-01-01 | 9 | 9 | 4.13% | 23 | $ 846.33 | $ 1,566.74 | Above |
| 2021 | Tildrakizumab (Ilumya, fne p-f syrng sc, 100 mg/1 ml, 1 ml)B | D5 Nonsteroidal products for inflammatory skin disorders | – | 2018-09-01 | 2021-08-01 | 2018-10-01 | 35 | 35 | 1.35% | 21 | $ 2,695.14 | $ 3,114.56 | Above |
| 2023 | Tirbanibulin (Klisyri, msn top u-d aint, 2.5 mg/dose, 250 mg) | D5 Nonsteroidal products for inflammatory skin disorders | – | 2021-02-01 | – | 2021-02-01 | – | – | 0.00% | 10 | $ 14.49 | $ 15.98 | NA |
| 2022 | Tirzepatide (Mounjaro, fpe vial sc, 10 mg/1 ml, 0.5 ml) | A10 Drugs used in diabetes | – | 2022-06-01 | 2023-10-01 | 2022-06-01 | 16 | 16 | 6.40% | 22 | $ 50.58 | $ 73.19 | Above |
| 2022 | Tixagevimab (Evusheld, fpd vial IM, 150 mg/1 ml + 150 mg/1 ml, 1.5 ml)B | J6 Sera and gamma-globulin | – | 2021-12-01 | 2022-05-01 | 2022-04-01 | 5 | 5 | 0.00% | 3 | $ 1,599.42 | $ 1,599.42 | NA |
| 2021 | Tralokinumab (Adtralza, fne p-f syrng sc, 150 mg/1 ml, 1 ml)B | D5 Nonsteroidal products for inflammatory skin disorders | – | 2021-06-01 | 2022-03-01 | 2022-02-01 | 9 | 9 | 1.18% | 16 | $ 189.56 | $ 396.19 | Above |
| 2021 | Trastuzumab deruxtecan (Enhertu, fqd inf dry bottle, 100 mg, NA vol)B,C | L1 Antineoplastics | – | 2019-12-01 | 2021-07-01 | 2019-12-01 | 19 | 19 | 9.06% | 24 | $ 999.41 | $ 2,330.62 | Above |
| 2023 | Tremelimumab (Imjudo, fqc infus.via/bot., 20 mg/1 ml, 15 ml)B,C,O | L1 Antineoplastics | – | 2022-11-01 | 2023-10-01 | 2022-11-01 | 11 | 11 | 1.02% | 15 | $ 16,793.05 | $ 30,154.39 | Above |
| 2021 | Trientine (Cuprior, abc film-ctd tabs, 150 mg, NA vol) | V3 All other therapeutic products | – | 1986-04-01 | 2022-07-01 | 1986-04-01 | 435 | 435 | 0.04% | 18 | $ 49.34 | $ 54.68 | NA |
| 2021 | Triheptanoin (Dojolvi, dga oral liquid, 4.8 g/5 ml, 500 ml)O | A16 Other alimentary tract and metabolism products | – | 2020-07-01 | – | 2020-07-01 | – | – | 0.00% | 2 | – | – | NA |
| 2022 | Ubrogepant (Ubrelvy, aaa tablets, 100 mg, NA vol) | N2 Analgesics | – | 2020-01-01 | 2023-04-01 | 2020-01-01 | 39 | 39 | 1.40% | 2 | – | – | NA |
| 2024 | Vaborbactam (Vabomere, fqd inf dry bottle, 1 g + 1 g, NA vol) | J1 Systemic antibacterials | – | 2017-10-01 | – | 2017-10-01 | – | – | 0.00% | 13 | $ 301.28 | $ 301.28 | NA |
| 2024 | Vaccine, chikungunya (Ixchiq, fpb vial dry, NA intstr, NA vol)B | J7 Vaccines | – | 2024-02-01 | 2024-11-01 | 2024-02-01 | 9 | 9 | 0.03% | 3 | $ 179.74 | $ 179.74 | Below |
| 2023 | Vaccine, respiratory syncytial virus (Abrysvo, fpb vial dry, 60 y, NA vol)B | J7 Vaccines | – | 2023-06-01 | 2023-09-01 | 2023-07-01 | 3 | 3 | 12.26% | 26 | $ 173.77 | $ 339.09 | Below |
| 2021 | Vaccine, sars-cov-2 non-replicating vector (Vaxzevria, fpd vial IM, NA intstr, 5 ml)B | J7 Vaccines | – | 2020-12-01 | 2021-03-01 | 2021-02-01 | 3 | 3 | 0.00% | 1 | – | – | NA |
| 2023 | Vericiguat (Verquvo, abc film-ctd tabs, 2.5 mg, NA vol) | C6 Other cardiovascular products | – | 2021-02-01 | 2023-09-01 | 2021-02-01 | 31 | 31 | 0.00% | 25 | $ 0.95 | $ 3.93 | Above |
| 2024 | Vorasidenib (Voranigo, abc film-ctd tabs, 40 mg, NA vol)C,O | L1 Antineoplastics | – | 2024-07-01 | 2025-03-01 | 2024-08-01 | 8 | 7 | 0.00% | 2 | $ 932.34 | $ 932.34 | NA |
| 2022 | Vorhyaluronidase alfa (Darzalex faspro, fpe vial sc, 120 mg/1 ml + 200 iu/1 ml, 15 ml)B | L1 Antineoplastics | – | 2007-02-01 | 2021-12-01 | 2007-02-01 | 178 | 178 | 0.03% | 20 | – | – | NA |
| 2023 | Vutrisiran (Amvuttra, fne p-f syrng sc, 50 mg/1 ml, 0.5 ml)O | N7 Other central nervous system drugs | – | 2022-07-01 | – | 2022-07-01 | – | – | 0.00% | 11 | $ 56,774.55 | $ 115,404.55 | NA |
| 2021 | Zanubrutinib (Brukinsa, aca capsules, 80 mg, NA vol)C,O | L1 Antineoplastics | – | 2019-12-01 | 2021-04-01 | 2019-12-01 | 16 | 16 | 7.42% | 21 | $ 26.17 | $ 59.60 | Above |
| 2024 | Zilucoplan (Zilbrysq, fne p-f syrng sc, 40 mg/1 ml, 0.81 ml)O | M5 Musculo-skeletal system | – | 2024-03-01 | – | – | – | – | 0.00% | 3 | $ 1,126.92 | $ 1,158.65 | NA |
| 2024 | Zolbetuximab (Vyloy, fqd inf dry bottle, 100 mg, NA vol)B,C,O | L1 Antineoplastics | – | 2024-06-01 | 2025-04-01 | 2024-11-01 | 10 | 10 | 0.00% | 5 | $ 396.15 | $ 709.60 | NA |
| 2025 | Nipocalimab (Imaavy)B | – | 2025-12-05 | No sales data in MIDAS® as of Q4-2025 – date of approval by FDA, EMA, and/or Health Canada. | |||||||||
| 2025 | Toripalimab (Loqtorzi)B,C | – | 2025-10-17 | ||||||||||
| 2025 | Garadacimab (Andembry)B | – | 2025-08-06 | ||||||||||
| 2025 | Deutivacaftor, tezacaftor, vanzacaftor calcium (Alyftrek) | – | 2025-07-21 | ||||||||||
| 2025 | Belantamab mafodotin (Blenrep)B,C | – | 2025-07-18 | ||||||||||
| 2025 | Osilodrostat phosphate (Isturisa) | – | 2025-07-03 | ||||||||||
| 2025 | Quizartinib hydrochloride (Vanflyta)C | – | 2025-06-09 | ||||||||||
| 2025 | Crovalimab (Piasky)B | – | 2025-06-04 | ||||||||||
| 2025 | Rozanolixizumab (Rystiggo)B | – | 2025-04-25 | ||||||||||
| 2025 | Cipaglucosidase alfa (Pombiliti)B | – | 2025-04-14 | ||||||||||
| 2025 | Antihemophilic factor VIII (Altuviiio)B | – | 2025-03-26 | ||||||||||
| 2025 | Tofersen (Qalsody) | – | 2025-02-28 | ||||||||||
| 2025 | Iptacopan hydrochloride (Fabhalta) | – | 2025-01-06 | ||||||||||
| 2025 | Olezarsen sodium (Tryngolza) | – | 2025-12-16 | ||||||||||
| 2025 | Vamorolone (Agamree) | – | 2025-09-29 | ||||||||||
| 2025 | Mirvetuximab soravtansine (Elahere)B,C | – | 2025-08-29 | ||||||||||
| 2025 | Bulevirtide acetate (Hepcludex)B | – | 2025-08-08 | ||||||||||
| 2025 | Omaveloxolone (Skyclarys) | – | 2025-03-13 | ||||||||||
| 2025 | Aprocitentan (Jeraygo) | – | 2025-12-23 | ||||||||||
| 2025 | Nemolizumab (Nemluvio)B | – | 2025-12-18 | ||||||||||
| 2025 | Tislelizumab (Tevimbra)B,C | – | 2025-12-18 | ||||||||||
| 2025 | Pegunigalsidase alfa (Elfabrio)B | – | 2025-12-09 | ||||||||||
| 2025 | Zuranolone (Zurzuvae) | – | 2025-12-05 | ||||||||||
| 2025 | Bempedoic acid (Nilemdo) | – | 2025-11-14 | ||||||||||
| 2025 | Lecanemab (Leqembi) | – | 2025-10-24 | ||||||||||
| 2025 | Pirtobrutinib (Jaypirca)C,O | – | 2025-10-17 | ||||||||||
| 2025 | Seladelpar lysine (Lyvdelzi)O | – | 2025-10-16 | ||||||||||
| 2025 | MRNA encoding SARS-CoV-2 spike protein ntd-rbd subdomains (Mnexspike)B | – | 2025-09-29 | ||||||||||
| 2025 | Delgocitinib (Anzupgo) | – | 2025-08-25 | ||||||||||
| 2025 | Lifileucel (Amtagvi)B,C | – | 2025-08-15 | ||||||||||
| 2025 | Elinzanetant (Lynkuet) | – | 2025-07-23 | ||||||||||
| 2025 | Repotrectinib (Augtyro)C,O | – | 2025-05-07 | ||||||||||
| 2025 | Elafibranor (Iqirvo)O | – | 2025-04-25 | ||||||||||
| 2025 | Teprotumumab (Tepezza)B,O | – | 2025-04-17 | ||||||||||
| 2025 | Tapinarof (Nduvra) | – | 2025-04-04 | ||||||||||
| 2025 | Sipavibart (Kavigale)B | – | 2025-03-21 | ||||||||||
| 2025 | Loncastuximab tesirine (Zynlonta)B,C,O | – | 2025-03-07 | ||||||||||
| 2025 | Lazertinib mesylate (Lazcluze)C | – | 2025-03-06 | ||||||||||
| 2025 | Fecal microbiota (Rebyota)B | – | 2025-03-05 | ||||||||||
| 2025 | Retifanlimab (Zynyz)B,C,O | – | 2025-02-06 | ||||||||||
| 2025 | Sepiapterin (Sephience)O | – | 2025-10-07 | ||||||||||
| 2025 | Oritavancin phosphate (Oritiniv) | – | 2025-09-12 | ||||||||||
| 2025 | Artesunate (Amivas-artesunate)O | – | 2025-07-04 | ||||||||||
| 2025 | Teplizumab (Tzield)B | – | 2025-05-05 | ||||||||||
| 2025 | Inavolisib (Itovebi)C | – | 2025-02-14 | ||||||||||
| 2025 | Delafloxacin meglumine (Baxdela) | – | 2025-01-17 | ||||||||||
Note: Availability and sales information refer to all forms and strengths of the medicine, while pricing and treatment costs are based on the highest-selling form and strength indicated. Sales are based on manufacturer list prices. Due to lack of sales data, only approval data is provided for all COVID-19 vaccines. Specialty medicines are indicated using the following abbreviations: B: biologic; C: cancer; G: gene therapy; O: orphan. * Level 2 of the Anatomical Classification of Pharmaceutical Products, as reported in MIDAS®; if unavailable in MIDAS®, the reporting is based on the Anatomical Therapeutic Chemical (ATC) Classification System maintained by the World Health Organization (WHO). § Canadian unit prices were retrieved from MIDAS®, where available. i Canadian unit price taken from CDA-AMC Reimbursement Review report. Data source: IQVIA MIDAS® Database, 2024(all rights reserved); Health Canada Notice of Compliance database.
| |||||||||||||
Data supplement C: Medicines approved in Canada that have met EDRD criteria* (through Q4-2025)
Data supplement C: Medicines approved in Canada that have met EDRD criteria* (through Q4-2025)
| Medicine (trade name)* | Notice of Compliance (NOC) date |
|---|---|
| Olezarsen sodium (Tryngolza) | 2025-12-16 |
| Nipocalimab (Imaavy)B | 2025-12-05 |
| Toripalimab (Loqtorzi)B,C | 2025-10-17 |
| Vamorolone (Agamree) | 2025-09-29 |
| Mirvetuximab soravtansine (Elahere)B,C | 2025-08-29 |
| Bulevirtide acetate (Hepcludex)B | 2025-08-08 |
| Garadacimab (Andembry)B | 2025-08-06 |
| Deutivacaftor, tezacaftor, vanzacaftor calcium (Alyftrek) | 2025-07-21 |
| Belantamab mafodotin (Blenrep)B,C | 2025-07-18 |
| Osilodrostat phosphate (Isturisa) | 2025-07-03 |
| Quizartinib hydrochloride (Vanflyta)C | 2025-06-09 |
| Crovalimab (Piasky)B | 2025-06-04 |
| Rozanolixizumab (Rystiggo)B | 2025-04-25 |
| Cipaglucosidase alfa (Pombiliti)B | 2025-04-14 |
| Antihemophilic factor VIII (Altuviiio)B | 2025-03-26 |
| Omaveloxolone (Skyclarys) | 2025-03-13 |
| Tofersen (Qalsody) | 2025-02-28 |
| Iptacopan hydrochloride (Fabhalta) | 2025-01-06 |
| Zolbetuximab (Vyloy)B,C | 2024-12-13 |
| Trofinetide (Daybue) | 2024-10-11 |
| Exagamglogene Autotemcel (Casgevy)B,C | 2024-09-23 |
| Avapritinib (Ayvakyt)C | 2024-09-18 |
| Tarlatamab (Imdelltra)B,C | 2024-09-11 |
| Sotatercept (Winrevair)B | 2024-08-28 |
| Vorasidenib (Voranigo)C | 2024-08-27 |
| Ivosidenib (Tibsovo)C | 2024-07-19 |
| Zilucoplan Sodium (Zilbrysq) | 2024-07-11 |
| Eplontersen Sodium (Wainua) | 2024-06-19 |
| Talquetamab (Talvey)B,C | 2024-04-30 |
| Metreleptin (Myalepta)B | 2024-01-17 |
| Inebilizumab (Uplizna)B | 2023-12-15 |
| Calaspargase Pegol (Asparlas)B,C | 2023-11-08 |
| Odevixibat (Bylvay) | 2023-10-30 |
| Etranacogene Dezaparvovec (Hemgenix)B | 2023-10-23 |
| Vutrisiran (Amvuttra) | 2023-10-18 |
| Epcoritamab (Epkinly / Tepkinly)B,C | 2023-10-13 |
| Evinacumab (Evkeeza)B | 2023-09-22 |
| Efgartigimod Alfa (Vyvgart)B | 2023-09-19 |
| Nivolumab, Relatlimab (Opdualag)B,C | 2023-09-13 |
| Tremelimumab (Imjudo)B,C | 2023-08-31 |
| Teclistamab (Tecvayli)B,C | 2023-07-26 |
| Maralixibat Chloride (Livmarli) | 2023-07-21 |
| Mirikizumab (Omvoh)B | 2023-07-20 |
| Setmelanotide Acetate (Imcivree) | 2023-05-05 |
| Glofitamab (Columvi)B,C | 2023-03-24 |
| Ciltacabtagene Autoleucel (Carvykti)B,C | 2023-02-09 |
| Amifampridine (Ruzurgi) | 2023-01-10 |
| Pegcetacoplan (Empaveli) | 2022-12-08 |
| Maribavir (Livtencity) | 2022-09-15 |
| Selumetinib Sulfate (Koselugo) | 2022-08-31 |
| Belzutifan (Welireg)C | 2022-07-11 |
| Asciminib Hydrochloride (Scemblix)C | 2022-06-22 |
| Tebentafusp (Kimmtrak)B,C | 2022-06-07 |
| Berotralstat Hydrochloride (Orladeyo) | 2022-06-02 |
| Mogamulizumab (Poteligeo)B,C | 2022-06-02 |
| Selinexor (Xpovio)C | 2022-05-31 |
| Capmatinib (Tabrecta)C | 2022-05-26 |
| Pegvaliase (Palynziq)B | 2022-03-30 |
| Belumosudil Mesylate (Rholistiq/Rezurock) | 2022-03-23 |
| Lumasiran Sodium (Oxlumo) | 2022-03-07 |
| Sacituzumab Govitecan (Trodelvy)B,C | 2021-09-24 |
| Pemigatinib (Pemazyre)C | 2021-09-17 |
| Elexacaftor / Tezacaftor / Ivacaftor And Ivacaftor (Trikafta) | 2021-06-18 |
| Selpercatinib (Retevmo)C | 2021-06-15 |
| Brexucabtagene Autoleucel (Tecartus)B,C | 2021-06-08 |
| Idecabtagene Vicleucel (Abecma)B,C | 2021-05-26 |
| Daunorubicin And Cytarabine (Vyxeos)C | 2021-04-29 |
| Risdiplam (Evrysdi) | 2021-04-14 |
| Encorafenib And Binimetinib (Braftovi And Mektovi)C | 2021-03-02 |
| Triheptanoin (Dojolvi) | 2021-02-15 |
| Azacitidine (Onureg)C | 2021-01-05 |
| Mecasermin (Increlex)B | 2020-12-17 |
| Onasemnogene Abeparvovec (Zolgensma)B | 2020-12-15 |
| Voretigene Neparvovec (Luxturna)B | 2020-10-13 |
| Givosiran (Givlaari) | 2020-10-09 |
| Luspatercept (Reblozyl)B | 2020-09-25 |
| Atezolizumab & Bevacizumab (Tecentriq & Avastin)B,C | 2020-08-07 |
| Fedratinib (Inrebic)C | 2020-07-27 |
| Polatuzumab Vedotin (Polivy)B,C | 2020-07-09 |
| Ripretinib (Qinlock)C | 2020-06-19 |
| Tucatinib (Tukysa)C | 2020-06-05 |
| Satralizumab (Enspryng)B | 2020-06-01 |
| Isatuximab (Sarclisa)B,C | 2020-04-29 |
| Glasdegib (Daurismo)C | 2020-04-28 |
| Caplacizumab (Cablivi)B | 2020-02-28 |
| Entrectinib (Rozlytrek)C | 2020-02-10 |
| Tafamidis (Vyndaqel) | 2020-01-20 |
| Gilteritinib (Xospata)C | 2019-12-23 |
| Gemtuzumab Ozogamicin (Mylotarg)B,C | 2019-11-28 |
| Cabozantinib (Cabometyx)C | 2019-11-08 |
| Ravulizumab (Ultomiris)B | 2019-08-28 |
| Acalabrutinib (Calquence)C | 2019-08-23 |
| Larotrectinib (Vitrakvi)C | 2019-07-10 |
| Niraparib (Zejula)C | 2019-06-27 |
| Tezacaftor/Ivacaftor (Symdeko) | 2019-06-27 |
| Patisiran (Onpattro) | 2019-06-07 |
| Cemiplimab (Libtayo)B,C | 2019-04-10 |
| Lorlatinib (Lorbrena)C | 2019-02-22 |
| Axicabtagene Ciloleucel (Yescarta)B,C | 2019-02-13 |
| Enasidenib (Idhifa)C | 2019-02-06 |
| Lutetium Lu 177 Dotatate (Lutathera)C | 2019-01-09 |
| Cerliponase Alfa (Brineura)B | 2018-12-19 |
| Burosumab (Crysvita)B | 2018-12-05 |
| Dinutuximab (Unituxin)C | 2018-11-28 |
| Pralatrexate (Folotyn)C | 2018-10-26 |
| Edaravone (Radicava) | 2018-10-03 |
| Inotersen (Tegsedi) | 2018-10-03 |
| Lanadelumab (Takhzyro)B | 2018-09-19 |
| Tisagenlecleucel (Kymriah)B,C | 2018-09-05 |
| Emicizumab (Hemlibra)B | 2018-08-02 |
| Brigatinib (Alunbrig)C | 2018-07-26 |
| Inotuzumab Ozogamicin (Besponsa)B,C | 2018-03-15 |
| Avelumab (Bavencio)B,C | 2017-12-18 |
| Sebelipase Alfa (Kanuma)B | 2017-12-15 |
| Olaratumab (Lartruvo)B,C | 2017-11-23 |
| Durvalumab (Imfinzi)B,C | 2017-11-03 |
| Migalastat (Galafold) | 2017-09-05 |
| Midostaurin (Rydapt)C | 2017-07-21 |
| Defibrotide (Defitelio)B | 2017-07-10 |
| Nusinersen (Spinraza) | 2017-06-29 |
| Cysteamine Bitartrate (Procysbi) | 2017-06-13 |
| Eliglustat (Cerdelga) | 2017-04-21 |
| Nitisinone (Orfadin) | 2016-12-13 |
| Nivolumab & Ipilimumab (Opdivo + Yervoy)B,C | 2016-10-26 |
| Venetoclax Obinutuzumab (Venclexta)C | 2016-09-30 |
| Alectinib (Alecensaro)C | 2016-09-29 |
| Alpha1-Proteinase Inhibitor (Human) (Zemaira)B | 2016-09-21 |
| Ixazomib (Ninlaro)C | 2016-08-04 |
| Osimertinib (Tagrisso)C | 2016-07-05 |
| Daratumumab (Darzalex)B,C | 2016-06-29 |
| Elotuzumab (Empliciti)B,C | 2016-06-21 |
| Olaparib (Lynparza)C | 2016-04-29 |
| Glycerol Phenylbutyrate (Ravicti) | 2016-03-18 |
| Cobimetinib (Cotellic)C | 2016-02-22 |
| Lumacaftor & Ivacaftor (Orkambi) | 2016-01-26 |
| Coagulation Factor Ix (Recombinant), Albumin Fusion Protein (Rix-Fp) (Idelvion)B | 2016-01-26 |
| Carfilzomib (Kyprolis)C | 2016-01-15 |
| Blinatumomab (Blincyto)B,C | 2015-12-22 |
| Nivolumab (Opdivo)B,C | 2015-09-25 |
| Teduglutide (Revestive)B | 2015-09-04 |
| Asfotase Alfa (Strensiq)B | 2015-08-14 |
| Ramucirumab (Cyramza)B,C | 2015-07-16 |
| Pembrolizumab (Keytruda)B,C | 2015-05-19 |
| Carglumic Acid (Carbaglu) | 2015-04-10 |
| Ponatinib (Iclusig)C | 2015-04-02 |
| Ceritinib (Zykadia)C | 2015-03-27 |
| Dabrafenib (Dabrafenib Mesylate) & Trametinib (Tafinlar + Mekinist)C | 2015-03-06 |
| Sodium Phenylbutyrate (Pheburane) | 2015-01-26 |
| Ibrutinib (Imbruvica)C | 2014-11-17 |
| Elosulfase Alfa (Vimizim)B | 2014-07-02 |
| Icatibant (Firazyr) | 2014-06-04 |
| Taliglucerase Alfa (Elelyso)B | 2014-05-29 |
| Lomitapide (Juxtapid) | 2014-02-04 |
| Pomalidomide (Pomalyst)C | 2014-01-20 |
| Romidepsin (Istodax)C | 2013-10-16 |
| Galsulfase (Naglazyme)B | 2013-09-16 |
| Trametinib (Mekinist)C | 2013-07-18 |
| Arsenic Trioxide (Trisenox)C | 2013-06-07 |
| Brentuximab Vedotin (Adcetris)B,C | 2013-02-01 |
| Ivacaftor (Kalydeco) | 2012-11-26 |
| C1 Esterase Inhibitor (Human) (Cinryze)B | 2012-10-19 |
| Crizotinib (Xalkori)C | 2012-04-25 |
| Vemurafenib (Zelboraf)C | 2012-02-15 |
| Ipilimumab (Yervoy)B,C | 2012-02-01 |
| Velaglucerase Alfa (Vpriv)B | 2010-10-01 |
| Trabectedin (Yondelis)C | 2010-05-13 |
| Sapropterin Dihydrochloride (Kuvan) | 2010-04-30 |
| Canakinumab (Ilaris)B | 2010-02-26 |
| Clofarabine (Clolar)C | 2009-07-16 |
| Vorinostat (Zolinza)C | 2009-06-11 |
| Romiplostim (Nplate)B | 2009-02-19 |
| Eculizumab (Soliris)B | 2009-01-28 |
| Lenalidomide (Revlimid)C | 2008-01-17 |
| Nelarabine (Atriance)C | 2007-09-22 |
| Idursulfase (Elaprase)B | 2007-06-13 |
| Alglucosidase (Myozyme)B | 2006-08-14 |
| Bevacizumab (Avastin)B,C | 2005-09-09 |
| Alfa 1-Proteinase Inhibitor (Human) (Prolastin-C)B | 2005-06-28 |
| Laronidase (Aldurazyme)B | 2004-05-31 |
| Miglustat (Zavesca) | 2004-03-31 |
| Agalsidase Alfa (Replagal)B | 2004-02-06 |
| Agalsidase Beta (Fabrazyme)B | 2004-01-23 |
| Treprostinil Sodium (Remodulin) | 2002-10-04 |
| Pegaspargase (Oncaspar)B,C | 1997-11-19 |
| Imiglucerase (Cerezyme)B | 1997-02-12 |